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ABSTRACT
Breast cancer is the most commonly diagnosed form of cancer in women, besides skin
cancer, and second only to lung cancer for cause of mortality. It is divided into three subtypes,
depending on different molecular or pathologic characteristics, including estrogen or progesterone
receptor-positive (ER/PR+), human epidermal growth factor receptor-2-positive (HER2+) and
triple negative breast cancer (TNBC). There are several therapies used to target these subtypes,
but there is still a chance that the cancer will recur into a more aggressive, resistant form even if
the therapies were successful before. This recurrence is believed to be due to the Cancer Stem Cell
(CSC) hypothesis which states that within the heterogeneous breast cancer tumor, there is a
population of CSCs that are responsible for resistance to therapy and tumor recurrence. Evidence
shows that Notch signaling, a pathway regulating several cellular processes, could be the reason
these CSCs survive, so new therapies are being developed to target Notch signaling. The problem
is, that Notch gene targets are not enough to provide a predictive response in breast cancer, so new
potential biomarkers have been identified to predict a response to therapy—such as DAXX protein.
This protein, which has been associated in pro-apoptotic pathways and gene expression repression,
has been shown to be inhibiting bulk cell proliferation in cell lines representative of all three breast
cancer subtypes. In a HER2+ and TNBC cell line this has been shown even in the presence of a
Notch inhibitor. Because of this, it was believed that DAXX expression may be inhibiting Notch
signaling.

ix

Results show that DAXX expression is required to limit proliferation of TNBC and other
subtypes such as the HER2+ (BT474) and not ER+ (MCF-7). Interestingly, DAXX depletion using
a DAXX siRNA decreases sensitivity of breast cancer cells to standard of care therapy in the
TNBC subtype, MDA-MB-231 cells, only. In other TNBC cell lines, this is not the case—showing
just how heterogenous this subtype is. Further, DAXX appears to be potentially regulating PARP
activity in MDA-MB-231 cells, which is key to stabilize cells that have some type of DNA damage,
since depletion of DAXX results in increased PARP-1 and PAR chains expression.
These results indicate that DAXX expression plays a role in limiting proliferation. The
mechanism by which this occurs is largely unknown. However, preliminary findings demonstrate
that a DNA damaging agent such as Carboplatin may induce JNK phosphorylation and activation.
This activation of JNK seems to be dependent on DAXX expression in MDA-MB-232 cells. We
assessed whether targeting JNK would be a novel therapeutic strategy in combination with
carboplatin. Results showed that the JNK inhibitor (SP600125) partially prevents the increase in
cell proliferation upon DAXX depletion. Results together suggest: 1. DAXX expression limits
proliferation of most subtypes of breast cancer; 2. DAXX expression is required for drug
sensitivity to standard of care but this differs in TNBC subtypes; 3. DAXX activates JNK to limit
proliferation in the mesenchymal stem-like subtype of TNBC; and 4. DAXX may regulate
poly(ADP) ribosylation (PAR) of PARP1 to possibly regulate the DNA damage response.

x

CHAPTER I
INTRODUCTION
Breast Cancer
Breast cancer is the most commonly diagnosed form of cancer in women, followed by skin
cancer, and second only to lung cancer for cause of mortality (Akram, Iqbal, Daniyal, & Khan,
2017; Desantis, Ma, Bryan, & Jemal, 2014). It is a disease that is characterized, like all other
cancers, as uncontrolled growth of cells due to mutations or abnormal expression changes of genes
that promote proliferation (Majeed et al., 2014). These hyper-proliferative cells are localized to
the luminal or basal cells within the breast organ. The disease is primarily caused by inherited
mutations in genes, such as BRCA1 or BRCA2, or by other factors such as obesity, alcohol,
hormone therapies or increased breast tissue density (Emens & Jaffee, 2005; Majeed et al., 2014).
However, thanks to new screening tools, the mortality rate of breast cancer for women in
developed countries has significantly declined since cancers are being detected earlier (Akram et
al., 2017). Screening for the disease includes several diagnostic exams such as mammograms,
ultrasounds, magnetic resonance imaging (MRI), computerized axial tomography (CAT) scans,
and position emission tomography (PET) scans. If there is an abnormal mass found, then a biopsy
is used to confirm cancer, subsequently leading to its pathological and molecular characterization.
Upon characterization, breast cancer can be divided into various subtypes, dependent on certain
pathologic or molecular characteristics of cancerous cells (Akram et al., 2017). There are five
known subtypes of breast cancer: normal-like, luminal A, luminal B, HER2-positive (HER2/
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ERBB2+), and triple negative (Anderson, Rosenberg, Prat, Perou, & Sherman, 2014). Nearly 70%
of breast cancer cases are Luminal A and B. These cancers express estrogen and or progesterone
receptors (ER/PR) and express wildtype levels of HER2. The proliferation of Luminal A and B
breast cancers are mainly driven by the female steroid hormone, 17-estradiol (Anderson et al.,
2014; Dai et al., 2015). The HER2+ subtype represents 15-25% of breast cancers. In these cancers,
there is an overexpression of the human epidermal growth factor 2 (HER2) protein which is due
to amplification of the ERBB2 proto-oncogene (Anderson et al., 2014; Fragomeni & Sciallis,
2018). The triple negative or also referred to as basal-like breast cancers lack expression of ER/PR
and overexpression of HER2 and represent nearly 10% of diagnosed breast cancers (Anderson et
al., 2014; Dai et al., 2015). The final subtype, normal-like, has similar features to Luminal A but
is considered a benign disease.
Estrogen Receptor Positive Breast Cancer and Signaling Pathways
In both females and males, hormones play a key role in developing and maintaining normal
sexual and reproductive function. Estrogen, specifically, or 17β-estradiol (E2) has biological
effects as a key regulator in various systems and tissues of the body such as mammary glands,
cardiovascular, musculoskeletal, immune, and central nervous systems (Hall, Couse, & Korach,
2001; Heldring et al., 2019). There are two nuclear receptors that mediate cellular signaling of E 2:
ERα and ERβ. Both receptors exhibit a high degree of homology thus they interact with the same
DNA response elements referred to as estrogen response elements (ERE) to mediate transcriptional
regulation. ERα is primarily expressed in the breast, cervix, and vagina, while ERβ expression is
much more limited to the ovary, prostate, testis, spleen, lung, hypothalamus, and thymus (Couse
et al., 1997; Hall et al., 2001). There are four distinct pathways in which estrogens and the ERs
regulate cellular processes [(summarized in figure 1 (Heldring et al., 2019)]. The classical ligand
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dependent pathway can be divided into two different yet similar pathways—direct or tethered. In
the direct ligand dependent pathway, ER is sequestered in an inhibitory complex with heat shock
proteins in the cytosol until the hormone binds (Hall et al., 2001). Once E2 binds within the ligand
binding domain, the monomeric receptor undergoes a conformation change releasing heat shock
proteins. The ER forms a dimer as an ER or ER homodimer or an ER/ heterodimer. Once
dimerization is facilitated, the receptor is in its active form and can enter the nucleus, bind its ERE,
recruit coregulators including histone acetyltransferases to initiate transcription. The tethered
ligand dependent pathway is similar to the classical pathway, except that the active ER binds to
another transcription factor, such as AP-1, and helps direct AP-1-driven transcription (Hall et al.,
2001). The non-genomic pathway also requires ligand binding to activate a receptor. However, in
this pathway, the “ER” is a non-nuclear, membrane bound receptor referred to as G Proteincoupled estrogen receptor (GPER). In this pathway, the ligand, E 2 binds the GPER at the plasma
membrane or at the mitochondrial membrane initiating a rapid kinase cascade including the
mitogen-activated protein kinase (MAPK) to induce a physiological response without regulating
gene expression (Heldring et al., 2019). Finally, the ligand independent pathway utilizes various
growth factors, such as epidermal growth factor (EGF) or insulin-like growth factor-1 (IGF-1), to
activate the ER in the absence of E 2. Either growth factor receptors can activate a cascade of
intracellular kinases to initiate phosphorylation of the ER, resulting in dimerization, nuclear
translocation, and binding to ERE to regulate transcription of genes in an E 2-independent manner
(Hall et al., 2001; Heldring et al., 2019). Proliferation of ER+ breast cancer is thought to be
promoted mainly by the classical pathway. However, the other pathways have been shown to
promote drug resistance to targeted therapies.
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Figure 1: Model Representing Four Molecular Pathways Used by Estrogen Receptors to
Regulate Genes or Physiological Processes.
Clinical Therapies Used to Treat ER+ Breast Cancer
Current clinical therapies to treat women with ER+ breast cancer include endocrine therapy
(ET) that target the synthesis of the ligand, estrogen or antagonize the ER through direct
competitive inhibition. As a first line therapy for women over the age of 50, the synthesis of
estrogen is targeted using aromatase inhibitors (AI). The enzyme, aromatase catalyzes the
conversion of androgens into estrogens therefore, inhibiting this process will deplete the amount
of estrogen available to interact with ER and has shown to do so effectively (Chen et al., 2007).
Examples of AIs include letrozole and anastrozole. However, long term exposure to this form of
ET eventually results in endocrine resistance, thus other therapies must be explored as second line
therapies to effectively treat the cancer. To directly target the ER, two types of antagonists are
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used: selective estrogen receptor modulators (SERM) or selective estrogen receptor degraders
(SERD). SERMs are cytostatic agents that modulate ER by competitively binding to the ligand
binding domain, inhibiting tissue specific estrogenic effects (Kaklamani & Gradishar, 2017).
Examples of SERMs include tamoxifen and raloxifene. Tamoxifen, a non-steroidal molecule, was
the first SERM to be approved for ER+ breast cancer (ref: Jordan) and more recently is first line
therapy for women under the age of 50 (ref: Rugo). SERDs are pure antagonists due to their
structural similarity to estrogen and their ability to promote the degradation of ER and
subsequently down regulate ER activity (Kaklamani & Gradishar, 2017). SERDs are categorized
as steroidal (i.e. fulvestrant), acrylic acids (i.e. AZD9496) or bases (i.e. arzoxifene) (Mcdonnell,
Wardell, Norris, & Biology, 2016). For a patient with ER+ breast cancer, the type of therapy they
receive is heavily dependent on menopausal status and can be a combination of the therapies
described.
Human Epidermal Growth Factor Receptor 2 Breast Cancer and Signaling Pathways
The human epidermal receptor tyrosine kinase-2 (HER2) is a type I, transmembrane,
receptor tyrosine kinase (RTK) and the second member of the HER family of RTKs which includes
HER1 (EGFR), HER3, and HER4. The HERs can homo- or hetero-dimerize upon growth factor
binding. Dimerization initiates auto- and trans-phosphorylation of tyrosine residues within the
intracellular tyrosine kinase domain (Hsu & Hung, 2017). These phosphorylated tyrosines recruit
src-homology-2 domain (SH2)-containing adaptor proteins that initiate activation of several kinase
cascades including PI3K/AKT, Ras/MEK/ERK, PKC, and JAK/STAT to promote cell survival,
proliferation, differentiation, motility, apoptosis, invasion, migration, adhesion and angiogenesis,
as shown in figure 2 (Hsu & Hung, 2017; Nautiyal, Kanwar, & Majumdar, 2010). HER2 is
considered an orphan receptor that does not need a growth factor to facilitate activation. As it is
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overexpressed in breast cancer, it can homodimerize with itself or heterodimerize with other
members (Veeraraghan et al., 2017). Although this family of proteins are critical for regulating
normal cellular processes, a consequence of dysregulating these processes is the development of
cancers. In HER2+ breast cancer, the ErbB2 proto-oncogene is amplified, resulting in an
overexpression of HER2 protein at the plasma membrane (Fragomeni & Sciallis, 2018). This
overexpression is sufficient to initiate breast cancer development. HER2+ breast cancer is an
aggressive form of breast cancer that frequently presents as metastatic with poorer survival rates
than ER+ breast cancer (Baselga, Coleman, Janni, & Kettering, 2017; Veeraraghan et al., 2017).
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Figure 2: The Various Signaling Pathways Initiated Upon Activation of HER (ERBB)
Receptor Proteins. The binding of the ligand leads to homo or heterodimerization of the receptors
which will activate several pathways. These pathways then result in cellular processes that are
related to maintaining homeostasis. Depending on which hetero or homodimer is formed will
dictate which pathway is activated.
Clinical Therapies Used to Treat HER2+ Breast Cancer
To treat HER2+ breast cancer, current therapies include first line use of humanized,
monoclonal antibodies: trastuzumab and pertuzumab. These antibodies bind to different
ectodomains of HER2 thus inhibiting dimerization, promoting receptor-mediated endocytosis,
downregulation of the receptor, decreased signaling, proliferation, and survival (Hsu & Hung,
2017). Second line therapies are used when resistance to antibodies occurs. These include tyrosine
kinase inhibitors (TKIs) such as lapatinib (Hurvitz, Gelmon, & Tolaney, 2017; Segovia-mendoza,
González-gonzález, Barrera, & Díaz, 2015) or neratinib (Baselga et al., 2017; Hsu & Hung, 2017;
Hurvitz et al., 2017) TKIs are small molecules that mimic ATP. They competitively bind within

8
the kinase domain of HER2 preventing ATP hydrolysis and thus tyrosine phosphorylation
(Segovia-mendoza et al., 2015).

The goal of anti-HER2 targeted therapy is inhibit signal

transduction pathways downstream of HER2 (Baselga et al., 2017). These compounds are most
effective when combined with chemotherapy agents such as capecitabine or paclitaxel. Unlike
lapatinib, neratinib is a pan-inhibitor because it interacts with the domain of several members of
the epidermal growth factor receptor (EGFR) family (Segovia-mendoza et al., 2015). Neratinib is
more effective than lapatinib.
Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is molecularly characterized as lacking expression
of ER, PR, and overexpression of HER2. (Pal, Childs, & Pegram, 2011). When compared to the
other breast cancer subtypes, TNBC is more aggressive, presents as an advanced stage disease,
and has an unfavorable or low prognosis (Fragomeni & Sciallis, 2018; Pal et al., 2011). TNBC
tumors are poorly differentiated making them more difficult to routinely diagnose due to
heterogeneity and have a high frequency to metastasize (Bianchini, Balko, Mayer, Sanders, &
Gianni, 2016; Jitariu, Cîmpean, & Ribatti, 2017). They develop primarily in pre-menopausal
women and progress rapidly. Histologically, most of TNBC’s are invasive mammary carcinomas
of no specific type, meaning they do not have any specific differentiating features and iare
molecularly characterized into several subtypes (Lehmann et al. 2011, Bianchini et al., 2016). It is
very difficult to characterize TNBC as there are no known targets that predict outcome and
response. This subtype is subdivided into at least 6 different categories, increasing the complexity
of this subtype in general (Lehmann et al., 2011). There have been some characterization of TNBC
suggesting that critical pathways are hyperactive. The PI3K/AKT/mTOR pathway is one of the
main signaling pathways that is responsible for a number of cellular events including proliferation
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and survival. Approximately 10% of TNBC have mutations genes within in the PI3K pathway
(Massihnia et al., 2016; Oualla et al., 2017). There is also evidence that the mTOR pathway is
more frequently activated in TNBC compared to other subtypes and that this activation correlates
to poorer prognosis (Massihnia et al., 2016).
Clinical Therapies Used to Treat Triple Negative Breast Cancer
Since TNBC doesn’t have many defining targets, such as ER or HER2, the primary form
of targeted therapy are DNA-damaging, tubulin-disrupting, cytotoxic agents in combination with
radiation therapy. Chemotherapies include platinum agents, such as cisplatin and carboplatin,
anthracyclines, such as doxorubicin, daunorubicin, epirubicin and idarubicin and taxanes, such as
paclitaxel and docetaxel (Mcgowan et al., 2017). Platinum agents take advantage of the fact that
cancer cells have poor DNA damage repair pathways. This provides the opportunity to promote
more DNA damage with the goal of accumulating enough DNA damage to induce cell death
(Bianchini et al., 2016). Cells that cannot properly repair this damage undergo programmed cell
death or apoptosis. Anthracyclines are a class of cardiotoxic drugs derived from the bacterium,
Streptomyces peucetius. This drug intercalates DNA by binding with topoisomerase enzymes to
form a topoisomerase-doxorubicin-DNA complex that will cause double stranded breaks in the
DNA, again taking advantage of the fact that these cancerous cells have poor DNA damage repair
pathways (Mcgowan et al., 2017). Taxanes are a class of diterpenes (large organic molecules)
derived from plants of the genus Taxus (Laurentiis & Press, 2015). Taxanes are mitotic inhibitors;
they function by disrupting microtubule function therefore inhibiting the process of cell division,
ultimately leading to cell death (Sibaud et al., 2017). As previously mentioned, the
PI3K/AKT/mTOR pathway is hyper-activated in some TNBC, so now there are also therapies
being generated to inhibit this pathway. DNA repair mechanisms are also being targeted because
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reducing this activity would increase and maintain DNA damage, inducing apoptosis. PARP
enzymes are key in these repair mechanisms. TNBC that contain mutations in key DNA repair
genes, BRCA1 and BRCA2, are sensitive to PARP inhibition. Therefore PARP inhibitors are being
developed to target TNBC with these DNA-repair deficiencies (Oualla et al., 2017).
DNA Damage Repair Mechanisms
Although there are some potential new therapies being generated, a primary form to
target cancers, mainly TNBC, is DNA damaging agents. Cancerous cells have defective DNA
damage repair mechanisms, making these therapies a very effective way to combat the disease.
In a healthy cell, there are five main repair DNA repair pathways which resolve single strand or
double strand breaks in the DNA (Chatterjee & Walker, 2018). Base excision repair (BER),
nucleotide excision repair (NER) and mismatch repair (MMR) are pathways involved in single
stranded breaks. BER is the primary mechanism used to remove base alterations in the DNA
(Chatterjee & Walker, 2018; Gomes, Menck, & Leandro, 2017). Once the damage or alteration is
identified, a DNA glycosylase excises the base and apurinic/apyrimidinic endonuclease 1 (AP1)
cleaves the phosphodiester chain at an AP site. DNA polymerase fills in the newly formed gap
and a ligase, such as DNA ligase 3 and XRCC1 (X-ray cross complementing) (Gomes et al.,
2017; Shafirovich & Geacintov, 2018; Whitaker, Schaich, Smith, Flynn, & City, 2017). NER is
similar to BER, but this repair mechanism is used when there is a bigger portion of the DNA to
removed and repaired, such as when there is a lesion that distort the DNA double helix
(Shafirovich & Geacintov, 2018). Platinums used in chemotherapy take advantage of the fact
that cancerous cells do not have effective NER repair mechanisms, since the mechanism of
action of the drug is to form adducts or cross links in the DNA with the drugs themselves
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(Bianchini et al., 2016). Two different NER repair systems exist: global genomic NER (GGNER) and transcription coupled NER (TC-NER)—which occurs when either the double helix
distortions made by lesions are sensed or when RNA polymerase is stalled because of lesions,
respectively (Shafirovich & Geacintov, 2018). Although there are two forms of NER initiated,
the overall basic process is still conserved. Upon damage recognition, signaling within the cell
will recruit NER factors (TFIIH, XPA, XPF, and XPG) that will excise almost 30 nucleotides on
the damaged strand, before DNA polymerase fills in what was removed (Abbotts & Wilson III,
2017; Shafirovich & Geacintov, 2018). In MMR, mismatched bases that arise after replication
are repaired. Mismatch repair proteins, MutS homolog (MSH), recognize the site in which the
incorrect base is in place; in humans this protein is the heterodimer MSH2/MSH6 (MSHα) which
recognizes the mismatch and 1-2 addition bases or the heterodimer MSH1/MSH2 (MSHβ) which
recognizes the mismatch and more than 2 bases (Chatterjee & Walker, 2018). The mismatched
base, and surrounding bases, on the nascent strand are incised by MutL homologs (MLH) and
DNA polymerase δ or ε synthesizes the new strand, followed by nick sealing (Carolina, Hill, &
Carolina, 2017; Chatterjee & Walker, 2018).
For double stranded breaks, the DNA repair mechanisms include homologous
recombination (HR) and canonical nonhomologous end joining (c-NHEJ). HR, the more
complex pathway to repair a DSB, uses an undamaged sister chromatid to repair the DNA and
does so to refrain from losing any of the sequence and several motor proteins to complete the
repair process. First, 3’ overhangs are created by resecting parts of the DNA with several
nucleases such as MRE11-RAD50-NBS complex (an endo/exonuclease) that resects 3’-5’
towards the break and exonuclease 1 (EXO1) which resects 5’-3’ away from the break (Shibata,
Jeggo, & Löbrich, 2018). Utilizing these overhangs, Replication Protein A (RPA) binds to the
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DNA in order to prevent spontaneous reannealing. Helicase protein BLM unwinds the DNA and
WRN promotes branch migration to allow for the recombinase RAD51 to mediate strand
invasion and resolve the DSB (Kaniecki, Tullio, Greene, Universitaria, & Biophysics, 2018;
Shibata et al., 2018). c-NHEJ, on the other hand, is mediated by Ku heterodimer proteins, that
dimerize at the DSB (Shibata et al., 2018). This dimerization recruits DNA-dependent protein
kinase catalytic subunits (DNA-PKcs) that create a complex with recruit other proteins such as
XRCC, which stabilize the ends of the break. XRCC then forms a complex with DNA ligase IV
to ligate the ends and finish the repair (Shibata et al., 2018). Figure 3 depicts pictorially these
pathways discussed.

Figure 3: Schematic Summarizing Five Main DNA Repair Mechanisms.
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Cancer Stem Cell Hypothesis
Drug resistance is a major cause of tumor relapse, metastatic spread, and mortality for
women with breast cancer. There is a hypothesis that recurring cancers arise from a subpopulation
of cells that have undergone oncogenic transformations that have acquired resistance to the initial
treatment (Celi, 2018). The subpopulation of cells are able to persist after treatment, and eventually
self-renew, giving rise to differentiated or stem-like daughter cells. A key pathway that promotes
survival of these persistant cells is Notch signaling (Dontu et al., Celi, 2018; Reya, Morrison,
Clarke, & Weissman, 2001; Shima, Yamada, Ishikawa, & Endo, 2017). These cells are referred to
as cancer stem cells (CSCs) and are thought to be a small population of cells within a
heterogeneous tumor. These CSCs are capable of driving tumor growth, progression and
metastasis because of the stem-like properties they possess (Celi, 2018; Charafe-Jauffret et al.,
2008; Kakarala & Wicha, 2008; Morrison, Schmidt, Lakhani, Reynolds, & Lopez, 2008; Shima et
al., 2017). Because breast cancers are molecularly complex, the cancer stem cell hypothesis,
depicted below in figure 3, has gained attention in the field as a means to explain why breast
cancer models and treatments are becoming more and more limited (Kakarala & Wicha, 2008).
Classically, it was believed that all cells in a cancerous tissue arise from mutations, making the
cells present equally malignant. However, current stem-cell biology studies are now sufficient to
directly test and attempt to support this hypothesis: a heterogeneous tumor contains several cell
types, including those that have stem-like properties (Charafe-Jauffret et al., 2008; Kakarala &
Wicha, 2008). As more information about CSCs come to light, so does the clinical implications
these cells in regards to treatment resistance. New targeted therapies are being developed to inhibit
survival of CSCs in combination with current standard of care with the goal of eliminating the
entire tumor and preventing recurrence (Reya et al., 2001). However, there are severe side effects
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associated with targeting pathways such as Notch due to both normal stem-cells and CSCs use the
Notch pathway.

Figure 4: Summary of the Cancer Stem Cell Hypothesis. In certain bulk tumors, there are
cancer cells that are sensitive to a specific therapy, depending on which type of Breast Cancer that
tumor is. After targeted therapy, the tumor shrinks, and the remaining cancer cells are eliminated
through chemotherapy, leading to regression of the tumor (top). However, this is not always the
case in breast cancer treatment, and it is now believed that within the heterogenous tumor, there
are stem-like cells that are not affected by targeted therapy or chemotherapy, thus persist after
treatment and can give rise to a new, resistant bulk tumor (bottom).
Notch Signaling
There are several lines of evidence that show CSCs survive by upregulating the Notch
signaling pathway. Notch receptors are highly conserved, single pass Type I transmembrane
proteins comprised of four homologs (Notch1, Notch2, Notch3, and Notch4) (Kopan & Ilagan,
2009; Previs, Coleman, Harris, & Sood, 2015). Notch signaling is a form of cell-cell
communication that results in regulating transcription of target genes (Kopan & Ilagan, 2009;
Previs et al., 2015). Other than maintaining the survival of stem cells, this pathway also regulates
other cellular processes such as self-renewal, cell fate determination, differentiation, proliferation,
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apoptosis, cell polarity, adhesion, and migration (Lamy, Ferreira, Sales, & Silva, 2017). Notch is
synthesized as a single polypeptide that undergoes a series of glycosylation events in the
endoplasmic reticulum and Golgi apparatus. Once in the Golgi, the single protein is cleaved into
two domains: extracellular (NEC) and transmembrane (NTM). The Notch receptor on the plasma
membrane is a heterodimeric protein comprised of the extracellular domain bound to the
transmembrane portion by a cation. To activate the canonical signaling pathway, one of the four
receptors on the signal receiving cell encounters its ligand on the signal sending cell. There are
five ligands that are known to induce Notch signaling and these are a family of DSL ligands, which
are characterized by the presence of a Delta, Serrate and Lag2 (DSL) domain (D’Souza, MelotyKapelle, & Weinmaster, 2010). There are five of these ligands in total that interact with the
receptors and activate the pathway: Delta-like1, 2, 3 and Jagged1 and 2 (D’Souza et al., 2010;
Kopan & Ilagan, 2009; Lamy et al., 2017). Once there is contact, the extracellular portion of the
Notch receptor is pulled away from the transmembrane portion by the ligand on the adjacent cell.
This contact also activates a series of proteolytic cleavages that will first remove a portion of the
transmembrane domain forming a product, NEXT. This first step is mediated by a
metalloproteinase, ADAM 10/17. This event by ADAM10/17 exposes the cleavage site for the γsecretase complex, that will cleave and release the Notch Intracellular Domain (NICD) (D’Souza
et al., 2010; Kopan & Ilagan, 2009; Kovall, Gebelein, Sprinzak, & Kopan, 2017). Within the cell,
the NICD translocates into the nucleus where it will interact with a transcriptional repressor, CSL,
leading to recruitment of other coactivators (i.e. Mastermind-Like family of proteins) that will derepress CSL and lead to activation of transcription (D’Souza et al., 2010; Talora et al., 2008).
Classic Notch target genes include those in the HES and HEY family of genes, CCND1/3, NF-κB
genes, p21KIP1, BCL2 and MYC (D’Souza et al., 2010; Lamy et al., 2017; Previs et al., 2015).
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A visual representation of Notch signaling is shown below in figure 4 (Takebe, Nguyen, & Yang,
2014). Dysregulation of this pathway has been implicated in several malignancies as it can be
oncogenic or tumor suppressive. Notch receptors and ligands are overexpressed in breast cancer
(Reedijk et al.). NICD1, 3, or 4 expression in the mammary gland leads to spontaneous mammary
tumors in mice (Callaghan et al.). Hyperactive Notch signaling has been shown to promote drug
resistance (Rizzo et al. 2008, Osipo et al. 2008), metastatic disease progression and tumor
recurrence (Pandya et al. 2011), which is why new therapies are being developed to target this
pathway (Previs et al., 2015).
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Figure 5: The Canonical Notch Signaling Pathway. The Notch receptor is synthesized in the
ER as a precursor before being cleaved and moving to the plasma membrane. At the membrane,
the receptor interacts with its ligand, initiating a series of cleavages that will eventually release the
NICD. This domain translocates to the nucleus, where it binds to CSL, recruit additional coactivators, and activate the transcription of target genes.
Inhibition of Notch Signaling
Since Notch signaling has been associated with maintaining the population of stem-like
cancer cells, new therapies are being developed in order to target this signaling pathway. There are
several ways to inhibit the Notch pathway, one of which being through the use of a drug that will
inhibit a key component in the pathway: the γ-secretase complex using a γ-secretase inhibitor
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(GSI) (Kovall et al., 2017; Lamy et al., 2017; Previs et al., 2015; Shih & Wang, 2007; Takebe et
al., 2014; Yuan et al., 2015). As previously mentioned, the γ-secretase complex cleaves NEXT
allowing for the release of the NICD to activate transcription of Notch target genes. However, by
using a GSI, this cleavage step is inhibited thus preventing release of NICD and de-repression of
CSL genes (D’Souza et al., 2010; Talora et al., 2008). Several GSIs have been synthesized and
proven to be quite effective. However, the side effects of inhibiting Notch signaling is a challenge
since the pathway is required for normal cellular functions (D’Souza et al., 2010; Previs et al.,
2015; Shih & Wang, 2007; Takebe et al., 2014). Also, there is a large amount of cytotoxicity
associated with the use of GSIs, specifically in the gastrointestinal tract, which is only worsened
by other cancer therapies such as chemotherapy. Thus, the use of GSIs pose a great challenge in
the clinic (Lamy et al., 2017; Previs et al., 2015; Shih & Wang, 2007; Takebe et al., 2014). Other
potential inhibitors of the Notch signaling pathway include Notch antibodies, antibody drug
conjugates (ADCs), blocking peptides or combination therapies (Lamy et al., 2017; Previs et al.,
2015; Takebe et al., 2014). Monoclonal antibodies can be used to inhibit either the receptors or the
ligands themselves or by blocking the cleavage of Notch by γ-secretases—a less cytotoxic solution
to GSI (Lamy et al., 2017; Takebe et al., 2014). ADCs are antibodies that are linked to a
biologically active cytotoxic drug to have the same targeting abilities as a Notch monoclonal
antibody with the ability of anticancer drugs (Takebe et al., 2014). Blocking peptides are
permeable peptides that block the interaction between NICD, CSL, and co-activators, such as
MAML, in the nucleus to prevent transcription (Takebe et al., 2014). All of which are still under
investigation.
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Clinical Biomarkers
Clinical biomarkers are detectable biological properties or molecules that can be used to
monitor disease progression, further characterize a disease, or assess the prognosis of the disease
(Günther, 2015). Because of this, they are used as prognostic markers for survival, critical for
management of the disease, type of therapy used, and possibly predictive of tumor response to the
therapy (Duffy, Harbeck, Nap, Molina, & Nicolini, 2017). Current biomarkers that are used for
prediction of response and survival outcomes remain ER, PR or HER2. Looking at these
biomarkers are limiting because they only predict if a certain tumor can benefit from receiving
endocrine therapy or anti-HER2 therapy (Duffy et al., 2017). Due to the interest in Notch signaling
as a promoter of CSCs, Notch gene targets (i.e. HES1 and HEY1) are considered possible
biomarkers for the activation status of Notch and presence of CSCs. There is work suggesting that
exosome-encapsulating miRNAs, serum levels, metabolites or multi-gene sequencing can provide
more precise biomarkers (Duffy et al., 2017; Günther, 2015; Joyce, Kerin, & Dwyer, 2016).
However, these methods have yet to provide predictive biomarkers of response to anti-Notch
therapy. Thus, there is a critical need to identify new predictive biomarkers for Notch activation,
presence of CSCs, and importantly response to anti-Notch therapy and overall survival outcomes
(Duffy et al., 2017; Harris et al., 2016).
Death Domain-Associated Protein 6 (DAXX)
Death Domain-Associated Protein 6 (DAXX) is a multifunctional nuclear and cytoplasmic
protein that is critical for several cellular processes. It has been shown to be able to shuttle between
both locations in response to various cellular stresses (Khelifi, Alcontres, & Salomoni, 2005). At
first, it was identified as a cytoplasmic protein that interacts with the Fas death domain to aid in
the activation of Fas-mediated cell death through JNK signaling, independently of FADD, hence
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the naming of the protein (Khelifi et al., 2005; Pluta, Earnshaw, & Goldberg, 1998; Salomoni &
Khelifi, 2006). DAXX also plays a role in other cell death pathways, such as TGFβ-induced
apoptosis, necrosis and autophagy (Salomoni & Khelifi, 2006). Conversely, DAXX may have an
anti-apoptotic role. To study the function of DAXX, siRNA was used to deplete the protein, but
interestingly, it was found that DAXX depletion led to an increase apoptosis and sensitized cells
to apoptosis-inducing factors (Michaelson & Leder, 2003; Salomoni & Khelifi, 2006). DAXX has
also been shown to be critical for embryonic development, since knockout studies in mice showed
embryonic lethality (Michaelson, Bader, Kuo, Kozak, & Leder, 1999; Salomoni & Khelifi, 2006).
Upon further characterization, it was determined that DAXX plays several roles in various cellular
processes not only in the cytoplasm but in the nucleus of cells. In the nucleus, it has been found to
associate with promyelocytic leukemia protein nuclear bodies (PML-NB), where it recruits DNA
methyltransferase1 (DMNT1) to methylate DNA at differentially methylated regions (DMR), to
repress gene expression (Salomoni & Khelifi, 2006). This methylation event, however, is not only
to repress gene expression but is also associated with differential histone modification (Voon &
Gibbons, 2016). These DMRs are important to maintain imprinted gene expression, and must
remain methylated (Voon & Gibbons, 2016). This methylation status has been shown to be
dependent of histone 3.3 (H3.3), a histone variant that is deposited at various repetitive sites that
are required to maintain heterochromatin stability. DAXX acts as an H3.3 chaperone and
associates with the chromatin remodeler, ATRX (α-thalassemia/mental retardation syndrome;
SWI/SNF) protein, to form a complex that is essential to deposit H3.3 at telomeres in chromatin
dense regions of the nucleus that can be modified with methylation of lysine 9 (H3K9me3) to
enable heterochromatin maintenance (Fan et al., 2019; Salomoni & Khelifi, 2006; Voon &
Gibbons, 2016; Voon & Wong, 2016). Mutations in this complex have been identified in various
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cancers and implicated in aiding cancerous cells in escaping apoptosis (promoting oncogenesis).
Thus, maintaining the proper function of this complex could be key in destroying cancerous tumor
cells (Dyer, Qadeer, Valle-garcia, & Bernstein, 2017; Fan et al., 2019).
C-Jun-N-Terminal Kinases
C-Jun-N-Terminal Kinases (JNK), also known as Stress-Activated Protein Kinases
(SAPK), are part of the Mitogen-Activated Protein Kinase (MAPK) family (Zeke, et al., 2016;
Derijard, et al., 1994; Hibi, et al., 1993). There are three genes that encode for JNK proteins, JNK1,
JNK2, and JNK3, and while JNK1 and JNK2 are present throughout the organism, JNK3 has tissuespecific expression patterns (Davis, 2000). These genes can be spliced into ten different splicing
variants, which correlate to different cellular functions. Within the protein structure of JNK, there
is an activating loop that contains either a threonine or tyrosine residue that can be phosphorylated
to activate JNK (Bogoyevitch & Kobe, 2006). Being that they are kinases, JNK proteins catalyze
the transfer of a phosphoryl group on ATP to a specific substrate in order to carry out a certain
function (Bogoyevitch & Kobe, 2006). JNK related substrates are either nuclear or cytoplasmic
and phosphorylation of these substrates can lead to functions that are either activating or inhibitory.
These substrates include the Jun family, activating transcription factor (ATF) family, Jun
dimerization Protein 2 (JDP2), B-cell lymphoma 2 (Bcl2) regulatory protein, Bcl2-associtated
death protein (BAD), Bcl2 associated X protein (BAX), protein kinase B (PKB or Akt), Elk-1, cMyc, Nuclear factor of activated T cells (NFAT) family, signal transducer and activator of
transcription (STAT) family, Pax family, tumor suppressor protein p53, as well as several nuclear
hormone receptors and proteins (Bogoyevitch & Kobe, 2006; Yazgan & Pfarr, 2002; McElhinny,
Li, & Wu, 2008; Leppa & Bohmann, 1999; Katz, Heinrich, & Aronheim, 2001; Gupta et al., 1996;
Yang, Whitmarsh, Davis, & Sharrocks, 1998; Yamana et al., 2002; Adler et al., 1997). There are

22
external stimuli, such as environmental cellular stresses, that results in phosphorylation of
substrates, initiating a cascade of regulatory events leading to a multitude of cellular processes.
These process are primarily dealing with the activity of transcription factors that can then regulate
oncogenic transformation, growth, differentiation, metabolism, cell division, movement, cell
survival and/or cell death (Zeke et al., 2016; Bogoyevitch & Kobe, 2006). Shown in figure 5, is a
summary of various JNK signaling pathways and the complexity of intracellular signal
transduction (Bogoyevitch & Kobe, 2006).

Figure 6: Overall JNK Signaling Pathways. Pathways are initiated by several external stimuli
that eventually will activate JNK, resulting in phosphorylation of several substrates within a cell.
This phosphorylation can then lead to further activation or inhibition of target substrate.
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JNK Signaling and Apoptosis
JNK signaling, as mentioned before, results in various cellular events via intracellular
signaling. The JNK signaling pathway has been shown to play a key role in both cell proliferation
and programmed cell death depending on the type and duration of extracellular signal
(Dhanasekaran & Reddy, 2017). In terms of cell death, it has been shown that JNK signalingmediated regulation of programmed cell death has been implicated in resistance to targeted
therapy, chemotherapy and cancer growth (Dhanasekaran & Reddy, 2017). All three JNKs have
been shown to play roles in apoptotic signaling both in the cytoplasm to regulate mitochondrialmediated apoptosis and in the nucleus. There are several apoptotic signals, such as oxidative stress
or DNA damage, that lead to a release of apoptotic proteins from the inner membrane space of the
mitochondria (Dhanasekaran & Reddy, 2011). However, it has been determined that JNK proteins
play a role in the modulation of these pro-apoptotic proteins in the mitochondria (Aoki et al., 2002;
Schroeter et al., 2003). JNK translocates to the mitochondria, and it has been shown to be required
for the release of cytochrome C, a protein required to initiate the caspase 9 cascade inducing
apoptosis (Dhanasekaran, 2011). On the other hand, extracellular signals can activate MAPK
which in turn phosphorylates JNK. Because of this event, JNK can translocate into the nucleus
where it can phosphorylate and subsequently activate c-Jun (Dhanasekaran, 2011; (Raman, Chen,
& Cobb, 2007). Upon activation, c-Jun can form, along with other nuclear proteins, activator
protein (AP-1) complexes which are responsible for regulating gene expression and in this case,
the expression of pro-apoptotic genes (Gutkind, Turjanski, & Vaque, 2007). Not only does an
activated JNK phosphorylate c-Jun, it can also phosphorylate other transcription factors that are
responsible for transcribing pro-apoptotic genes or decrease the expression of pro-survival genes
(Dhanasekaran & Reddy, 2011, 2017; Larhammar et al., 2017). Figure 6 summarizes both nuclear
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and mitochondrial pro-apoptotic events that are initiated by JNK signaling, as previously described
(Dhanasekaran & Reddy, 2017).

Figure 7: The Role of JNK Signaling in Both Nuclear and Mitochondrial Related Apoptosis.
Transactivation of transcriptions factors (TFs) are those that have been previous described.

CHAPTER II
PRELIMINARY DATA, HYPOTHESIS AND SPECIFIC AIMS
Preliminary Data
Since breast cancer recurrence continues to be a problem for many patients that undergo
remission, specific gene targets are used to predict how well a patient will respond to a therapy.
Currently, Notch gene targets HES1 and HEY1 are being used since this signaling pathway has
been implicated in maintaining the survival of CSCs. However, these gene targets offer no
predictive value, which is why a biomarker trial was initiated to elucidate potential new Notch
targets, that predict therapeutic response. Twenty-two women with ER+ breast cancer were
enrolled in the trial. An initial biopsy was taken prior to beginning 2 weeks of endocrine therapy
(tamoxifen or an aromatase inhibitor). A second biopsy was taken at this point and for 10 more
days these women were treated with endocrine therapy in combination with a GSI, MRK-0752.
After treatment, these women underwent their final surgery, and the RNA from the samples
collected on day 0, 14 and 25 were analyzed by real-time PCR and Affymetrics microarray. Several
gene transcripts were found to be significantly upregulated or downregulated (figure 7). To test
whether these genes were required for anti-Notch efficacy by the GSI, overexpression or depletion
studies were conducted for each gene under no treatment or GSI treatment, using the ER+ MCF-7
cell line, followed by assessment of CSC survival as measured by mammosphere forming
efficiency (MFE) (figure 8). Only one gene was identified to be necessary for anti-CSC efficacy
by the GSI, Death-associated protein 6 (DAXX).
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Figure 8: Upregulation of DAXX shown in Clinical Trial Patients Treated with ET and GSI.
Data from clinical trial that assessed the expression of several genes from 22 patient tumors that
first underwent endocrine therapy and treatment with GSI. (A) Heat map of the gene transcripts
whose varying gene expression was due to the GSI treatment. (B) The expression of 4 transcripts,
highlighted in the microarray, to determine the efficacy of the GSI used from the tissue samples,
showing that out of these four transcripts, DAXX is the only one upregulated.

Figure 9: Effects of Depleting DAXX in CSC Population of an ER+ Cell Line. (A) Western
blot showing that not only can DAXX be depleted by siRNA, but treatment of GSI also upregulate
expression of the protein. (B) CSC assay showing effects of depleting DAXX under conditions
with or without GSI (top). Quantification of the assay seen on the bottom under each condition
tested.
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Since DAXX was shown to be the gene of interest from the clinical trial and in vitro results
using ER+ cells, more in vitro studies were performed to assess the role of DAXX on bulk cell
proliferation using other breast cancer cell lines (HER2+ and TNBC). The cells were transfected
with a control or DAXX siRNA to knockdown the DAXX protein. Cells were then treated, daily,
with the vehicle (DMSO), 5μM MRK-003 GSI or Pfizer GSI for up to 7 days followed by the
measurement of cell proliferation using the Countess Cell Counter. As figure 9 shows, DAXX
depletion by siRNA increases proliferation of HER2+, BT474 cells in the absence of GSI
treatment. In contrast, the Pfizer GSI has little effect on proliferation, while the MRK-003 GSI
significantly inhibits proliferation of BT474 cells . Under any GSI treatment, DAXX depletion has
little effect on proliferation. These results suggest two possible conclusions: 1) DAXX limits
proliferation of HER2+, BT474 cells through a Notch dependent mechanism and/or 2) DAXX
inhibits Notch to promote resistance to a GSI.

Figure 10: Bulk Cell Proliferation Data in BT474 Trastuzumab Resistant Cells: BT474 TR
cells were transfected with control siRNA (SCBi) and DAXX siRNA for 48 hours. After
transfection, the cells were grown in 10% FBS DMEM in three 6-well plates and treated daily for
seven day utilizing two different GSIs: Pfizer (A) and MRK-003 (B). the fold increase proliferation
over the course of the experiment was calculated and statistical significance was calculated using
an ANOVA and multiple comparison test. (C) shows the confirmation of the DAXX knockdown
using the relative gene expression via RT-qPCR.
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Similar results were observed in TNBC cells (MDA-MB-231). These cells have a high
proliferation rate and surprisingly, DAXX depletion further increased proliferation from 20 to 80fold in the absence of GSI (figure 10). Like the results from BT474 cells, the Pfizer GSI was
ineffective at inhibiting proliferation of MDA-MB-231 cells, while the MRK-003 GSI
significantly blocked growth. DAXX depletion increased sensitivity to a GSI, suggesting that
DAXX limits the proliferation of TNBC by possibly inhibiting Notch and thus promotes resistance
to a GSI.

Figure 11: Bulk Cell Proliferation Data in MDA-MB-231 Cells: MDA-MB-231 cells were
transfected with control siRNA (SCBi) and DAXX siRNA for 48 hours. After transfection, the
cells were grown in 5% FBS IMEM in three 6-well plates and treated daily for seven day utilizing
two different GSIs: Pfizer (A) and MRK-003 (B). the fold increase proliferation over the course
of the experiment was calculated and statistical significance was calculated using an ANOVA and
multiple comparison test. (C) shows the confirmation of the DAXX knockdown in a Western blot
(left) and the relative gene expression via RT-qPCR (right).
Preliminary data suggest that DAXX is required to limit the proliferative capacity of
HER2+ and TNBC cells, possibly by inhibiting Notch signaling. These results indicate that there
could be a cross-regulation of DAXX and Notch that is necessary to limit proliferation of breast
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cancer cells and possibly sensitivity to growth inhibiting agents, such as carboplatin, the current
standard of care (figure 11).

Figure 12: Growth Progression Studies of MDA-MB-231 Cells. Proliferation of MDA-MB-231
cells treated with GSI MRK-003 (A), carboplatin (B), or in combinations of the two treatments
(C), were measured over the course of 7 days. Varying concentrations of each drug were compared
against one another, until the combination treatments, where the IC50 of carboplatin was used and
kept constant throughout.
Hypothesis
Based on previous reports and new preliminary data, the following hypothesis is proposed: DAXX
limits proliferation of distinct breast cancer subtypes by attenuating Notch signaling. In
addition, DAXX expression could be a potential predictive biomarker of response to current
targeted therapy. The following aims will determine if DAXX is a key regulator of breast cancer
growth and establish if its expression is to modulate sensitivity to targeted and/or cytotoxic
therapies.

30
Specific Aims
Aim 1. Determine if DAXX is a Suppressor of Breast Cancer Cells of Distinct Subtypes by
Regulating the Notch Pathway.
Preliminary data show that DAXX expression is required to limit bulk cell proliferation of
two out of the three breast cancer subtypes: HER2+ and TNBC. By siRNA, the expression of
DAXX is depleted, and the proliferation over the course of 7 days increases by 2-fold in BT474
cells (HER2+) and almost 4-fold in MDA-MB-231 cells (TNBC). The requirement of DAXX to
limit proliferation of these breast cancer cells seems to be dependent on Notch signaling. However,
what is not known, is whether DAXX expression modulates Notch signaling to limit the
proliferation and survival of breast CSCs from distinct subtypes of breast cancer.
Aim 1a: To assess the role of Notch signaling, real-time PCR will be performed under
control and Dominant Negative Mastermind-like (DN-MAML1) conditions to detect changes in
cellular phenotypes when Notch signaling is disrupted via the detection of Notch target gene
transcripts (i.e. HES1, HEY1, HES4, HEYL, CMYC, and CCND1). Under these conditions, bulk
cell proliferation studies and stem cell assays, assessed by mammosphere forming efficiency, will
be conducted using ER+ MCF-7, HER2+ BT474, and TNBC MDA-MB-231 cells to see if the
results compare to the preliminary data that utilizes GSI to inhibit Notch signaling.
Aim 1b: To assess the role of DAXX on Notch signaling, real-time PCR will be performed
under control and DAXX siRNA-transfected conditions to detect Notch target gene transcripts (i.e.
HES1, HEY1, HES4, HEYL, CMYC, and CCND1). Additional bulk cell proliferation studies and
stem cell assays, as assessed by mammosphere forming efficiency, will be conducted under control
conditions (scrambled siRNA) and DAXX depletion (DAXX siRNA) using ER+ MCF-7, HER2+
BT474, and TNBC MDA-MB-231 cells.
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Aim 2. Determine if DAXX Expression is Regulated by Current Therapy and Modulates
Sensitivity.
Preliminary data from the TNBC MDA-MB-231 cells show that DAXX expression is
required to limit proliferation through a Notch dependent mechanism. This indicates that the
expression of DAXX may attenuate the efficacy of the GSI.
Aim 2a: To assess whether DAXX expression is modulated in response to other types of
therapies, TNBC cells will be treated with carboplatin. HER2+ cells will be treated with anti-HER2
therapy such as lapatinib or trastuzumab. ER+ cells will be treated with anti-estrogens, including
estrogen deprivation, tamoxifen, or fulvestrant. DAXX expression will be measured by real-time
PCR and Western blotting after 24- and 72-hours post-treatment. Further, based on preliminary
data generated by former members of the Osipo laboratory, it was shown that carboplatin increased
expression of Notch receptors and sensitivity to the MRK-003 GSI in TNBC. Based on these
results, carboplatin could decrease DAXX, thus enhancing Notch signaling and sensitivity to
Notch blockade. Thus, if RNA and protein expression results demonstrate that therapy, such as
carboplatin, decreases DAXX expression, then DAXX will be ectopically overexpressed to assess
proliferation and expression of Notch genes and targets in response to a GSI, carboplatin, and the
combination. Similar studies will be conducted in ER+ and HER2+ breast cancer cells using the
appropriate standard of care therapy.
Aim 2b: Alternatively, DAXX may limit proliferation of cells, thus decreasing efficacy to
carboplatin in TNBC cell, to anti-HER2 therapy in HER2+ cells, and/or to anti-estrogens in ER+
cells. To assess the role of DAXX as a promoter of resistance to current therapy, DAXX will be
depleted using siRNA and different breast cancer subtypes will be treated with carboplatin
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(TNBC), lapatinib (HER2+) or fulvestrant (ER+), then proliferation and CSC survival will be
measured.

CHAPTER III
MATERIALS AND METHODS
Materials
Cell Culture
Each Breast Cancer cell line was maintained and cultured in the appropriate medium and incubated
at 37°C with 5% CO2. Listed below are the cell lines used and the medium in which they were
cultured for maintenance or experiments.
MDA-MB-231: MDA-MB-231 Breast Cancer cells were acquired from Dr. Ruth Lupu
(Mayo Clinic, Rochester, MN). These cells were cultured in Improved Minimal Essential Medium
(IMEM) enhanced with 5% Fetal Bovine Serum (FBS; Corning Cellgro, Corning Inc., Corning,
NY), 1% Nonessential Amino Acids (NEAA; Corning Cellgro), and 1% L-Glutamine (Corning
Cellgro).
BT474 TR and TS: BT474 Breast Cancer cells that are sensitive to Trastuzumab (TS) were
received from American Type Culture Collection depository (ATCC, Rockland, MD) and cultured
in Dulbecco’s Modification of Eagle’s Medium (DMEM; Corning Cellgro) enhanced with 10%
FBS (Corning Cellgro), 1% NEAA (Corning Cellgro), and 1% L-Glutamine (Corning Cellgro).
BT474 cells were treated over 6 months with increasing concentrations of Trastuzumab until they
acquired resistance to the treatment by Dr. Clodia Osipo (Osipo et al., 2008. Oncogene) (TR).
These cells are cultured in 10µg/mL of Trastuzumab to maintain resistance.
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MCF-7: MCF-7 Breast Cancer cells were provided by Dr. V. Craig Jordan (University of
Texas, M.D. Anderson Cancer Center, Houston, TX). These cells were cultured in Roswell Park
Memorial Institute medium (RPMI 1640; Corning Cellgro) enhanced with 10% FBS (Corning
Cellgro), 1% NEAA (Corning Cellgro), and 1% L-Glutamine (Corning Cellgro). When these cells
were deprived of Estrogen, they were cultured in Roswell Park Memorial Institute medium without
phenol red (RPMI 1640 w/o phenol red) and enhanced with 10% charcoal stripped FBS (Corning
Cellgro), 1% NEAA (Corning Cellgro), and 1% L-Glutamine (Corning Cellgro).
MDA-MB-468: MDA-MB-468 Breast Cancer cells were cultured in Dulbecco’s
Modification of Eagles Medium (DMEM, Corning Cellgro) and enhanced in the same manner as
described above.
Plasmid DNA
DAXX: Human death domain associated protein (DAXX) expression plasmid consists of
the entire ORF with a Myc-DDK expression tag cloned into a pCMV6-entry vector. (OriGene,
Rockville, MD, #RC226603)
HES1: Human hairy and enhancer of split 1 (HES1) expression plasmid consists of the
entire ORF with a Myc-DDK expression tag at the end of the sequence cloned into a pCMV6entry vector. (OriGene, #RC211709)
Small Interfering RNA (siRNA)
DAXXi: DAXX siRNA (GE Healthcare Dharmacon, Inc., Lafayette, CO) was used to
knockdown DAXX protein. The siRNA came in a set of 4 (J-004420-05, J-004420-06, J-00442007, J-004420-08) to knockdown the entire protein. DAXX siRNA was transfected using
Lipofectamine RNAi iMax (Invitrogen, Carlsbad, CA, #13778150) and Opti-MEM (Gibco;
Thermo Fisher Scientific, Waltham, MA, #31985070).
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HES1i: Hes-1 siRNA (Santa Cruz, sc-37938) was used to knock down Hes1 protein. Hes1
siRNA was transfected using Lipofectamine RNAi iMax (Invitrogen) and Opti-MEM (Gibco;
Thermo Fisher Scientific).
As a control, Scrambled siRNA purchased from Integrated DNA Technologies, IDT, was used
(Integrated DNA Technologies, Coralville, IA, custom-made; no reference number).
Antibodies
The DAXX antibody is monoclonal and purchased from Cell Signaling Technologies (Cell
Signaling Technology, Danvers, MA, #4533). Total JNK and Phosphorylated-JNK (T183/Y185)
antibodies are monoclonal rabbitand purchased from Cell Signaling (Cell Signaling, #9258 and
#4668). The Hes-1 antibody is polyclonal rabbit purcchased from Santa Cruz Biotechnology
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, sc-25392). Monoclonal mouse anti-β-Actin
antibody was used as the loading control for all Western Blot analysis and cytoplasmic localization
studies (Sigma-Aldrich, St. Louis, MO, A-5441). Polyclonal rabbit anti-Lamin B (M-20) antibody
was used as the loading control for nuclear localization studies via Western Blot analysis (Santa
Cruz, sc-6217).
Primers
All primers used in Reverse Transcription, quantitative real-time Polymerase Chain Reaction (RTqPCR) were designed using the NCBI Primer Blast and purchased from Invitrogen. They were
resuspended in Nuclease-Free water to create working stocks with a concentration of 50µM. Listed
in the table below are the sequences for each primer used.
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Table 1. Forward and Reverse Sequences of the Primers Used to Target Notch Signaling
Gene Targets and Notch Receptors.

Drug Treatments
MRK-003 GSI: A γ-secretase inhibitor, MRK-003, was provided from Merck Oncology
and Co. (Whitehouse Station, NJ) and resuspended in Dimethyl sulfoxide (DMSO) from Thermo
Fisher Scientific (Thermo Fisher Scientific, 67-68-5) to create a 10mM stock solution. The
working concentrations for cell treatments were 5µM or 10µM.
Pfizer GSI: A γ-secretase inhibitor was purchased from Pfizer (Pfizer, New York, NY, PF03084014) and resuspended in DMSO to create a 10mM stock solution. The working
concentration for cell treatments were 5µM or 10µM.
Carboplatin: Carboplatin, a DNA damaging agent, was purchased from Sigma Aldrich
(Sigma, C2538) and resuspended in DMSO (Thermo Fisher) to make a stock solution of 10mM.
The stock was diluted to make various concentrations—1.25mM, 2.5mM, and 5.0mM. The
working concentrations for cell treatments were 1.25µM, 2.5µM, 5.0µM and 10µM.
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Estradiol: 17β-Estradiol was purchased from Sigma-Aldrich (Sigma-Aldrich, #50-28-2)
and resuspended in 200 proof absolute molecular grade ethanol from Thermo Fisher Scientific
(Thermo Fisher Scientific, BP2818100) to make a 5mM solution. A 5µM stock solution was then
created and the working concentration for cell treatments was 5nM.
4-Hyrdroxytamoxifen: 4-Hydroxytamoxifen (4OHT) was purchased from Selleck
Chemicals (Selleck Chemicals, Houston, TX, S7827) and resuspended in 200 proof molecular
grade ethanol (Thermo Fisher) to make a solution of 40mM. A working stock solution of 100µM
was created by diluting the 40mM stock solution and from this various concentrations of the drug
were created, ranging from 0.0001µM to 10µM, in logarithmic increases. The concentration for
cell treatments were 0.0001nM, 0.001nM, 0.01nM 0.1nM, 1.0nM, 10nM and 100nM.
Fulvestrant: Fulvestrant was purchased from Selleck Chemicals (Selleck Chemicals,
S1191) and resuspended in 200 proof molecular grade ethanol (Thermo Fisher) to make a solution
of 100mM. A working stock solution of 100µM was created by diluting the 100mM stock solution
and from this various concentrations of the drug were created, ranging from 0.0001µM to 10µM,
in logarithmic increases. The concentration for cell treatments were 0.0001nM, 0.001nM, 0.01nM
0.1nM, 1.0nM, 10nM and 100nM
Trastuzumab: Trastuzumab (Herceptin) was received from Genentech (Genentech Inc.,
South San Francisco, CA, 50242-134-68) as a 22mg lyophilized pellet. A working concentration
of 22µg/mL was created by adding sterile PBS. The stock was diluted with Phosphate-Buffered
Saline (PBS, Corning Cellgro) to create various concentrations for cell treatments—2.5µg/mL,
5.0µg/mL, 10µg/mL and 20µg/mL.
SP600125: JNK inhibitor (SP600125) was purchased from Selleck Chemicals (Selleck
Chemicals, S1460) and resuspended in DMSO (Thermo Fisher) to create a 50mM stock
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concentration. The stock was diluted to make various concentrations, 10mM, 5mM and 1mM and
the working concentrations for cell treatments were 10µM, 5µM and 1µM.
Experimental Methods
Transfection
Protein Knockdown. In 10cm sterile tissue culture treated plates, cells were seeded the
day before transfection at nearly 80% confluency. On the day of the transfection, 2mL of OptiMEM media were mixed with 120µL of Lipofectamine RNAi iMAX. This solution was left to
incubate at room temperature for 5 minutes, to form the lipofectamine mixture in the media. In
separate tubes, 1mL of Opti-MEM media was mixed with 60µL of either control (scrambled)
siRNA or the target protein siRNA. These solutions were also left to incubate for 5 minutes at
room temperature. Then, 1mL of the Lipofectamine RNAi iMax+Opti-MEM solution were added
to each tube with Opti-MEM+siRNA. These solutions were left to incubate for 20 minutes at room
temperature. This was to allow the now formed, positively charged liposomes to interact with the
negatively charged siRNA and encapsulate the siRNA for delivery. Fresh media was added to the
plates while the siRNA incubated with the Lipofectamine RNAi iMax+Opti-MEM solution (9mL).
After the solutions had incubated, each were added carefully to each plate of cells, in a dropwise
manner and left to incubate for 48hrs at 37°C. This allowed for the liposomes to be endocytosed
by the cells to release the siRNA once it had entered the cell. The siRNA is then able to travel to
the nucleus where it can bind to the target mRNA, and degrade the transcript thus knocking down
the protein of interest. When transfecting in a 6cm dish, the same process was followed but the
amounts of reagent and siRNA used were decreased by a factor of 2.6, which was the ratio of the
10cm dish surface area to the 6cm dish surface area. This was to compensate for the change in
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surface area of the smaller plate. When transfecting in a 6-well tissue culture plate, the amounts
were decreased by a factor of 5.85.
Overexpression of Protein by DNA Plasmid. In 10cm sterile tissue culture treated plates,
cells were plated the day before the transfection at about 80% confluency. On the day of the
transfection, 1mL of Opti-MEM media were mixed with 24μL of polyethyleneimine (PEI). This
solution was left to incubate at room temperature for 10 minutes. Then 6μg of plasmid DNA were
added to the PEI+Opti-MEM solution and left to incubate at room temperature for 20 minutes.
This allows for the PEI to interact with the plasmid DNA to form a complex of polymer and DNA,
polyplexes, which are positively charged, condense the DNA and provide protection from
degradation. Fresh media was added to the plates during incubation (9mL). After incubation, the
PEI+Opti-MEM+plasmid DNA solutions were carefully added to the plates, in a dropwise manner
and left to incubate for 24hrs at 37°C. Once the positively charge polyplexes encounter the
negatively charged cell surface, the DNA is released into the cell, where it can travel to the nucleus
and transiently express the plasmid—resulting in the protein of interest to be overexpressed. When
transfecting in a 6cm dish, the same process was followed but the amounts of reagent and plasmid
DNA were decreased by a factor of 2.6, which was the ration of the 10cm dish surface area to the
6cm dish surface area, compensating for the change in surface area of the smaller plate. When
transfecting in a 6-well tissue culture plate, the amounts were decreased by a factor of 5.85.
Western Blotting
Bicinchoninic Acid (BCA) Assay. Lysis buffer was prepared as shown in the table below.
Cells could either be trypsinized and pelleted prior to adding lysis buffer or directly lysed and
scraped off with a rubber cell scraper. After the addition of the buffer, cells were incubated on ice
for 20 minutes. After incubation, cells were sonicated twice for 10 seconds at 20% amplification.
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Protein standards of bovine serum albumin (BSA) of varying concentrations, from 0 to 10μg/mL,
were added in duplicate to a 96-well plate to create a standard curve. 10μL of each sample were
added to the 96-well plate, as well, in duplicate. 200μL of BCA working reagent were added to
each well (10mL of Reagent A mixed with 200μL of Reagent B). The 96-well plate was incubated
at 37°C for 30 minutes. After incubation, the plate was read by a microplate reader. The total
amount of protein was determined by comparing the absorbance values of the samples to that of
the standard curve, with an R² value greater than 0.98, generated. Western blot samples were then
prepared with the known amounts of protein from each sample collected, 2X sample buffer with
2-Mercaptoethanol and additional lysis buffer, if needed. The samples were then boiled on a hot
plate at 95°C for 10 minutes and stored at 4°C.
Table 2. Reagents Needed and Amounts to Make 5mL of Lysis Buffer.

Gel Preparation. For Western blot analysis, Sodium Dodecyl Sulfate (SDS) gels were
prepared, to separate proteins based on molecular weight. Two portions of the gel were casted: the
stacking portion, where the samples are loaded, and the resolving portion, where the samples run
through and separate. Depending on the protein of interest and its molecular weight, an 8% or 10%
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acrylamide gel was created, with the higher percentage used to visualize proteins of lower
molecular weight. Listed in the table below are the reagents and amounts needed to make both
portions of the gel. A clean, short glass plate was placed in front of a clean, 1.5mm tall glass spacer
plate, and secured inside a casting frame, with the bottom of the plates completely flat. The casting
frame was then secured into place in the casting stand. 8mL of the resolving solution were added
in between the two plates. 1mL of isopropanol was added to the top of the solution, to flatten the
top of the gel forming. The gel was left to solidify for 20 minutes. Once the resolving portion of
the gel was casted, the isopropanol was rinsed off and the stacking portion was added. 2mL of the
stacking solution were added to the top of the gel and a 1.5mm gel comb was place on top of the
gel, in the stacking solution. (either 10 or 15 well). The gel was left to solidify again for 20 minutes
and was ready to be used.
Table 3. List of Reagents and Amounts for Both an 8% and 10% SDS Resolving Gel.

Table 4. List of Reagents and Amounts for the Stacking Gel.
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Western Blot. Begin with preparation of separating and stacking gels first and then the
apparatus set up. The Western blot separating apparatus was filled with 1X Running buffer (80mL
10X Running buffer + 720mL ddH2O). The gels were inserted inside, with the short glass plate
facing inward. All protein samples were boiled and sonicated prior to loading onto gels. Protein
separation was conducted using 150V for 1 hour or until separation was completed. To transfer
the proteins from the gel to the nitrocellulose membrane, the transfer apparatus was set up (with a
buffer tank, electrode assembly and two gel holder cassettes). 2 sponges, 2 pieces of Whatman
filter paper and 1 nitrocellulose membrane (per gel) were soaked with 1X Transfer Buffer (80mL
10X Transfer buffer + 560mL of ddH2O + 160mL of methanol) . The gels were then carefully
taken out from the glass plates and placed on the nitrocellulose membrane- sandwiched between
two pieces of filter paper, oriented in the correct direction that would transfer the ladder onto the
left side of the membrane. The filter papers-nitrocellulose membrane-gel were then smoothened
using a flat spatula to remove any potential bubbles that would have interfered with the transfer.
The filter papers-nitrocellulose membrane-gel bundle was then placed in between two buffersoaked sponges and placed inside a gel holder cassette, where the orientation of the gel coincided
with the black portion of the cassette. The cassette was then placed inside the electrode assembly,
with the black portion of electrode assembly facing the back and the black portion of the cassette
facing the same way. The buffer tank was filled with the remaining 1X Transfer Buffer and two
icepacks were placed in the remaining space of the buffer tank, to ovoid over-heating. The transfer
of proteins from gel to nitrocellulose membrane was conducted at 100V for 1 hour. After transfer,
membranes were cut at the appropriate weight marker, depending on the protein of interest. Pieces
of membrane were then blocked and gently rocked for an hour at room temperature with 3mL of
nonfat milk (5g of powdered nonfat milk in 100mL of TBST), to prevent nonspecific binding of
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antibodies to the membrane. After blocking, 3mL of nonfat milk with 3μL of primary antibody,
specific to the protein of interest, were added to the membranes and left to rock gently overnight,
at 4°C. The following day, membranes were washed with 1X TBST and rocked for 10 minutes (3
times/each). After the final wash, 3mL of nonfat milk and 2μL of secondary antibody (either anti
mouse or anti rabbit) were added to the membranes and rocked gently for 1 hour at room
temperature. The membranes were washed again, as previously described, and then developed
using Pierce ECL Western Blotting Substrate and pieces of film. If needed, then SuperSignal West
PICO Plus Chemiluminescent Substrate was used to develop proteins that were more difficult to
detect.
Growth Assay
After transfection, cells were seeded in sterile 12-well, tissue culture plates, in triplicate
wells. The number of cells seeded varied among cell type and are listed in the table below. Cells
were treated daily for a total of seven days with varying concentrations of the standard of care for
each cell type: Triple negative breast cancer cell lines were treated with Carboplatin (MDA-MB231, MDA-MB-468); HER2+ breast cancer cells lines were treated with Trastuzumab (BT474
Trastuzumab sensitive, BT474 Trastuzumab resistant); ER+ breast cancer cell lines were treated
with 4-Hydroxytamoxifen, Fulvestrant or were deprived of Estrogen (MCF-7). After seven days
of treatment, cells were washed with PBS, trypsinized and counted. The total volume of the
resuspended cells was recorded to calculate the total cell count and measure the fold change.
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Table 5. Number of Cells Seeded per Well for Each Cell Line in Growth Assays.

Real-Time Polymerase Chain Reaction (PCR)
RNA Extraction. Cells were collected in 300μL of Ambio TRIzol Reagent, either scraped
directly from tissue culture plates or spun down and resuspended in the reagent. At this point, cells
can either be stored at -80°C or the RNA can be extracted immediately. To the cells suspended in
TrIzol, 50μL of 1-Bromo-3-chloropropane (BCP) were added to the suspension and vortexed for
approximately 15 seconds. The suspensions were then incubated at room temperature for 5 minutes
and then centrifuged for 15 minutes at 14,000rpm at 4°C. At this point, the Zymo Research Directzol RNA Miniprep Plus kit was followed (with a few modifications to the protocol in the kit). The
clear, aqueous phase was removed and placed in a new 1.5mL Eppendorf tube. Equal parts of 200
proof molecular grade ethanol were added to each tube and the entire sample was placed in a
Zymo-Spin IIICG Column within a collection tube. The samples were centrifuged at top speed for
30 seconds. 200μL of Direct-zol RNA PreWash were added to the column and centrifuged for the
same time and speed as previously described. This was done twice to the column. Then 500μL of
RNA Wash Buffer were added to the column and centrifuged at top speed for 2 minutes. An
additional 30 seconds of centrifuging the column were done to ensure that it was completely dry
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of any wash buffers. Then 50μL of DNase/RNase-Free Water were added directly to the column
matrix and centrifuged for 30 seconds at top speed to elute the RNA. The samples were placed
immediately on ice and the concentration of RNA was measured using the NanoDrop 2000.
Reverse Transcription (RT). To generate 25ng/μL of cDNA, 0.5μg of RNA are needed
per reaction. From the concentration of RNA measured with the NanoDrop 2000, the amount of
RNA needed per reaction to generate that amount of cDNA was calculated and diluted with water
if necessary. The components for each reaction are listed in the table below. Once every component
was mixed together, a BioSystems 2720 Thermal Cycler was used to reverse transcribe the RNA
over a series of temperatures and times that will anneal, polymerize the DNA and deactivate the
reverse transcription enzyme to make several copies of cDNA.
Table 6: Components for a 50μL RT-PCR Reaction

Quantitative Real Time PCR (qRT-PCR). cDNA generated as described in the method
above was then used in a qRT-PCR analysis, which uses the SYBR Green Master Mix and primers
to target and amplify certain transcripts in the cDNA sample and quantifies the relative quantity
of gene transcripts expressed over the course of the reaction. The components and quantity to set
up the reaction are listed in the table below. Once each reaction was prepared in a 96-well plate,
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the Applied Biosystems Step One Plus Real-Time thermocycler was used to initiate the reaction.
From the reaction, the instrument recorded cycle threshold (CT) values, which are the number of
cycles required for the fluorescent signal to cross a specific threshold. Using these values, the 2ΔΔCT

calculation was performed to achieve relative fold change of a gene transcript normalized to

HPRT and compared to a control sample.
Table 7: Components For a 12.5μL qRT-PCR Reaction

Cell Cycle
MDA-MB-231 cells were seeded at a density of 400,000 cell in 6cm dishes and transfected
with siRNA or expression plasmids (refer to Transfection methods). After transfection, cells were
tripsinized and seeded into two plates, under each condition (control siRNA vs. DAXX siRNA
and pCMV6 vs. DAXX overexpression vector). Remaining cells were centrifuged and lysed to
collect protein to confirm DAXX knockdown or overexpression (refer to Western Blotting
methods). Cells were treated with either DMSO or 5μM Carboplatin for one day. On the day of
the assay, cells were washed, trypsinized and individualized. All media and PBS were kept,
collecting all cells regardless if they were dead or alive. The cells were centrifuged at 1200rpm for
3 minutes and washed with 2mL of cold FACS buffer (5% FBS in PBS). Cells were then
resuspended in 250μL RNase A, that was diluted 1:1000 in PBS, and incubated first for 15 minutes
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at 37°C and then for 5 minutes at room temperature. In the dark, 250μL of Propidium Iodine (PI),
diluted 1:10 in PBS, were added to the cells, and they were left to incubate in the dark for at least
an hour before running flow cytometry on the BD FACS Canto II instrument.
Cell Fractionation
Cells were seeded in a 10cm tissue culture dish and treated over the course of seven days,
collecting cells at an initial (no treatment), three-day, and seven-day time point. A protease
inhibitor solution (PIS) was made by adding 50μL of a protease inhibitor cocktail and 20μL of
PMSF to 200μL PBS. The medium was aspirated from the cells and they were washed with PBS.
750mL of PBS were added to each plate and using a rubber cell scraper, cells were scraped off the
plate and placed in 1.5mL Eppendorf tubes on ice. The cells were then centrifuged at 2,300rpm
for 5 minutes at 4°C and the PBS was aspirated. 500μL of CER I, made from adding 10μL PIS to
500μL of CER I buffer from the Thermo Scientific NE-PER Nuclear and Cytoplasmic Extraction
Reagents Kit, were added to the pellet and vortexed twice for 10 seconds. The suspension was
incubated on ice for 10 minutes. Then, 25μL of the CER II Buffer was added to the suspension,
vortexed for 10 seconds, incubated for 1 minute on ice and vortexed again. The suspension was
pelleted by centrifuging for 5 minutes at 14,000rpm at 4°C. The cytoplasmic fraction, the
supernatant, was collected and placed on ice. To the remaining pellet, 250μL of working NER
Buffer were added, made by adding 20μL pf PIS to 1mL of NER Buffer from the kit. The new
suspension was vortexed for 10 seconds twice and placed back on ice. This was repeated every 10
minutes for 40 minutes. During the 40 minutes, the suspension was also pipetted vigorously to
forcefully break the nuclear membrane during this time. Then, the suspension was centrifuged for
10 minutes at 14,000rpm at 4°C and the remaining supernatant, the nuclear fraction, was collected
and placed on ice. BCA assay (refer to Western Blotting Methods above) was performed on the

48
different fractions to determine the concentration of protein present—except only 5μL of sample
and 4X sample buffer were used instead of 10μL and 2X sample buffer.

CHAPTER IV
RESULTS
Specific Aim 1: Determine if DAXX is a Suppressor of Breast Cancer Cells of Distinct
Subtypes by Regulating the Notch Pathway.
Notch signaling regulates diverse several cellular processes including cell survival,
proliferation, and cell death. Preliminary data show that DAXX may be limiting overall bulk
cell proliferation in various subtypes of breast cancer to different degrees. Preliminary data
also show that DAXX is upregulated in response to GSI when combined with endocrine
therapy in ER+ MCF-7 cells and is required for the efficacy of the GSI to inhibit cancer stem
cells derived from this subtype. In HER2+ and triple negative cell lines, expression of the
DAXX protein is necessary for the GSI to inhibit bulk cell proliferation. The preliminary data
suggest that DAXX is necessary for the Notch inhibitor to effectively inhibit proliferation of
at least three cell lines representing three breast cancer subtypes. Therefore, the goal of this
first aim is to determine if DAXX acts upstream or downstream of the Notch signaling pathway
to inhibit breast cancer cell survival.
DAXX Regulates, HES1, a Notch Target Transcription Factor, Possibly Independent of
the Signaling Pathway.
To determine if DAXX expression regulates the Notch pathway, DAXX was depleted in
the triple negative cell line, MDA-MB-231, and treated with a GSI. Measurement of Notch
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target gene transcripts (HES1, HEY1, CMYC, HEY2, NOTCH3, and NOTCH4) was
performed by RT-qPCR. If DAXX is a regulator of Notch signaling, then depletion of DAXX
would lead to an increase or a decrease in Notch target gene transcripts. Upon measuring the
expression of several Notch target transcripts, DAXX depletion by siRNA results in decreased
expression of HES1, HEY1, and CMYC (figure 12A), but increased expression of other genes,
HEY2, NOTCH3, and NOTCH4 (figure 12B). Thus, it appears that DAXX expression is
required for both the activation and repression of the Notch pathway. Of the gene transcripts
measured, only HES1 expression was significantly decreased upon DAXX depletion. These
results suggest that DAXX is required for expression of the Notch target gene, HES1, a
transcriptional repressor. Thus, it is possible that DAXX inhibits cell proliferation of MDAMB-231 and other cells by activating HES1.

Figure 13: Expression of DAXX Affects the Expression of Several Notch Target Genes.
MDA-MB-231 cells were transfected with control or DAXX siRNA for 48 hours. After
transfection, cells were grown in 5% FBS IMEM in 6-well plates and treated for 24 hours with
two different GSIs. After treatment, RNA was extracted from the cells and cDNA was synthesized.
The relative gene expression of various Notch targets was measured by RT-qPCR. Genes that
require DAXX expression to be (A) activated or (B) suppressed are shown.
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To determine if DAXX inhibits growth of MDA-MB-231 cells through HES1, HES1 was
either depleted or overexpressed and cell proliferation was measured. If DAXX is inhibiting
proliferation of breast cancer cells through the activation of HES1, then depleting HES1 will result
in an increase in proliferation in a similar manner as when DAXX is depleted. Additionally, if this
is the case, then overexpression of HES1 should limit proliferation of these cells, regardless of
DAXX expression.
When cells are depleted of HES1 (figure 13B), bulk cell proliferation of MDA-MB-231
cells significantly increases (figure 13A). However, when HES1 is overexpressed (figure 13D and
E), there is little effect on bulk cell proliferation (figure 13C, second column). In fact, bulk cell
proliferation is increased when DAXX is depleted, even when HES1 is overexpressed, contrary to
what was expected (third and fourth column). Together, these data demonstrate that the effects
of DAXX on cell proliferation of MDA-MB-231 cells may be independent of HES1, one of the
major targets of Notch signaling.

A.

B.

C.

D.

E.
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Figure 14: Expression and Regulation of DAXX May Be Notch-Independent. MDA-MB-231
cells were transfected with either control, DAXX or HES1 siRNA. Additionally, cells were also
transfected with an empty vector or an expression vector containing a CMV promoter and HES1
gene sequence. After transfection, cells were grown in 5% FBS IMEM for 7 days. The fold change
in proliferation of cells in HES1 knockdown conditions (A.) or in various combinations of HES1
or DAXX depletion along with HES1 overexpression (C.) was measured after 7 days. Knockdown
of HES1 alone or HES1 and DAXX with either expression vector was confirmed by gene
expression via RT-qPCR (B. and D., respectively). Overexpression of HES1 was confirmed by
gene expression as well via RT-qPCR (E.)
Specific Aim 2: Determine if DAXX Expression is Modulated by Current Standard of Care
Therapy and is Required for Drug Sensitivity.
Breast cancers that are treated with current standard of care eventually acquire resistance.
What is not known is whether DAXX expression is a critical regulator of drug sensitivity.
Therefore, the goals of this aim are to determine: 1. if current therapies regulates expression of
DAXX and 2. if DAXX regulates sensitivity of these breast cancer cells to their subtype-specific
therapy.
Sensitivity of ER+ Breast Cancer Cells to Endocrine Therapy is Not Dependent on DAXX.
To investigate the effects of DAXX expression on ER+ breast cancer therapy, MCF-7 cells
were transfected with DAXX siRNA and treated with endocrine therapy that directly inhibits the
activity of the ER for 7 days. If DAXX expression modulates sensitivity to endocrine therapy in
MCF-7 cells, then depleting DAXX will either increase or decrease the concentration necessary to
achieve 50% inhibition of proliferation (IC50). Proliferation as measured by fold increase of live
cells at day 7 or % growth is decreased in a concentration dependent manner in response to either
4-hydroxytamoxifen (4-OHT) (figure 14A and B) or fulvestrant (figure 14C and D), two forms
of endocrine therapy. DAXX expression has very little effect on drug sensitivity, since the
proliferation continues to decrease in response to 4-OHT or fulvestrant regardless of DAXX
depletion. The negative control for this experiment was the vehicle, ethanol.
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A.

B.

C.

D.

Figure 15: DAXX is Required to Limit Proliferation but Only has a Slight Effect on the
Sensitivity of ER+ Breast Cancer Therapies. MCF-7 cells were transfected with either control
or DAXX siRNA for 48 hours. After transfection, cells were then grown in 10% FBS RPMI
without phenol red and treated daily with either 4-hydroxytamoxifen or fulvestrant for 7 days,
daily. After 7 days, the fold change in proliferation in those cells treated with 4-OHT (A.) of
fulvestrant ( C.) was measured as well as the percent growth (B., D. respectively) were measured.

Table 8: Statistical Significance P-values for Proliferation of DAXX-Depleted versus DAXXExpressing MCF-7 Cells Treated with 4-Hydroxytamoxifen.
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Table 9: Statistical Significance P-values for Proliferation of DAXX-depleted versus DAXXexpressing MCF-7 Cells Treated with Fulvestrant.

Differential Expression of DAXX in Response to Endocrine or Targeted Therapies
To investigate if 4-OHT or fulvestrant modulates DAXX protein expression in ER+ breast
cancer, MCF-7 cells treated daily for three days with either the vehicle control (ethanol), estradiol
(positive control), 4-OHT, or fulvestrant. The expression of DAXX protein was detected by
Western blot analysis. If endocrine therapy modulates DAXX protein expression, then DAXX
expression will either increase or decrease in response to the therapy. A DAXX siRNA was used
to confirm the detection of the DAXX protein and confirm knockdown for other studies described
above. Estradiol increases DAXX protein expression compared to the control ethanol-treated
group (figure 15, first column to third column). Three forms of endocrine therapy, estrogen
deprivation (figure 15, third column to first column), 4-OHT (figure 15, fifth column to first
column), or fulvestrant (figure 15, seventh column to first column) decrease expression of the
DAXX protein to varying degrees. Also, the Western blot confirms that the DAXX siRNA was
effective at decreasing DAXX levels.
Together, these data show that DAXX protein expression is increased by estrogen but is not
required for cell proliferation nor drug sensitivity of an ER+ breast cancer cell line.
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Figure 16: DAXX Expression is Modulated Differently Based on the Form of Endocrine
Therapy Given. MCF-7 cells were transfected with either control or DAXX siRNA for 48 hours.
After transfection, cells were grown in 10% FBS RMPI without phenol red for three days, while
treating with the drugs listed above daily. Cells were then lysed, and protein was collected and
measured to create samples for Western blotting. Protein was separated and visualized via Western
blot analysis.
DAXX Limits Proliferation of Both Sensitive and Resistant HER2+ Cell Lines but has Little
Effect on Sensitivty to Anti-HER2 Therapy.
The Osipo lab showed previously that trastuzumab increases Notch1 expression to
maintain resistance in HER2+ breast cancer cells (Osipo et al., 2008; Baker at al., 2018). Further,
it was shown that Notch-1 directly regulates DAXX expression (Albain et al., 2014). To determine
if DAXX is the mediator of resistance to trastuzumab, BT474 trastuzumab sensitive and resistant
cells were transfected with DAXX siRNA and treated daily for 7 days with increasing
concentrations of trastuzumab. Proliferation was assessed by measuring the fold change in live
cells at 7 days and calculating the percent growth. If DAXX expression modulates sensititvity to
trastuzumab, then depleting DAXX in either cell line should result in an increase in cell
proliferation regardless of the concentration. DAXX depletion resulted in increased proliferation
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of both trastuzumab sensitive (figure 16A) and resistant (figure 16C) cells regardless of
trastuzumab treatment. The percent growth of each cell line showed that the sensitive cells
remained sensitive to trastuzumab (figure 16B), while the resistant cells remained resistant (figure
16D), independent of DAXX expression.
These data suggest that while DAXX limits the proliferation of HER2+, BT474 breast
cancer cells, this function of DAXX does change sensitivity to trastuzumab.

A.

C.

B.

D.

Figure 17: DAXX Expression is Modulated Differently Based on the Form of Endocrine
Therapy Given. MCF-7 cells were transfected with either control or DAXX siRNA for 48 hours.
After transfection, cells were grown in 10% FBS RMPI without phenol red for three days, while
treating with the drugs listed above daily. Cells were then lysed, and protein was collected and
measured to create samples for Western blotting. Protein was separated and visualized via Western
blot analysis.
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Table 10: Statistical Significance P-values for Proliferation of DAXX-depleted versus DAXXexpressing BT474 Sensitive Cells.

Table 11: Statistical Significance P-values for Proliferation of DAXX-depleted versus DAXXexpressing BT474 Resistant Cells.

Differential Effects of Trastuzumab on DAXX Protein Expression in HER2+ Sensitive and
Resistant Cell Lines.
To assess whether trastuzumab modulates DAXX protein expression, both BT474 sensitive
and resistant cell lysates were treated with trastuzumab and subjected to Western blotting to detect
DAXX. A Notch inhibitor (GSI) was used as a positive control as previous work has shown Notch
modulates DAXX protein expression. DAXX protein levels were decreased by the GSI in BT474
sensitive cells (figure 17A), while having little effect in resistant cells (figure 17B). Similarly,
trastuzumab decreased DAXX protein expression in sensitive cells (figure 17A), but has little
effect in resistant cells (figure 17B). The figure below also confirms that DAXX has been depleted
in these cells by siRNA. These data with the proliferation studies suggest that DAXX is required
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to limit proliferation of HER2+ breast cancer cells but is not required for trastuzumab sensitivity.
Further, these results indicate that while trastuzumab decreases DAXX expression in sensitive
cells, this decrease in DAXX may not be linked to proliferation or sensitivity to trastuzumab.

A.

B.

Figure 18: DAXX Expression Upon Treatment with Trastuzumab is Only Affected in a
Sensitive HER2+ Cell Line. BT474 trastuzumab sensitive (A.) and resistant (B.) cells were
transfected with either control or DAXX siRNA for 48 hours. After transfection, cells were growth
in 10% FBS DMEM for three days and treated with either GSI or trastuzumab daily. The
concentration of trastuzumab used were determined using the growth data. After treatment, cells
were lysed, and protein was collected and measured to create samples for Western blotting. Protein
was separated and visualized via Western blot analysis.
DAXX Limits Peoliferation in a Triple Negative Cell Line and Modulates Sensitivity to Some
Chemotherapies.
In order to determine if DAXX is required to modulate sensitivity to chemotherapy such
as carboplatin, in a triple negative cell line, MDA-MB-231 cells were transfected with DAXX
siRNA and treated with carboplatin daily for 7 days. If DAXX expression is required for drug
sensitivity, then sensitivity to carboplatin will increase when DAXX is expressed and decreased
when DAXX is depleted. When DAXX is depleted in the absence of carboplatin, the proliferation
of these cells significantly increases from 50 fold to over 75 fold (figure 18A). In addition, the
Inhibitory concentration at 50% cell proliferation (IC50) of carboplatin is 2.5μM when DAXX is
expressed compared to IC50 = 5μM when DAXX is depleted (figure 18B).
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A.

B.

Figure 19: DAXX is Required for Both Limiting Cellular Proliferation Significantly and
Drug Sensitivity in a Triple Negative Cell Line. MDA-MB-231 cells were transfected with
either control siRNA or DAXX siRNA for 48 hours. After transfection, cells were grown in 5%
FBS IMEM for 7 days and treated with carboplatin daily. After treatment the fold change in
proliferation (A.) and percent growth (B.) were calculated.
Table 12: Statistical Significance P-values for Proliferation of DAXX-depleted versus
DAXX-expressing MDA-MB-231Cells.

Carboplatin Increases DAXX Protein Expression.
To determine if carboplatin modulates DAXX expression in the MDA-MB-231 cells, cells
were transfected with DAXX siRNA and treated with either a GSI or carboplatin daily for three
days. If DAXX expression if required for sensitivity to carboplatin, then treating the cells with
carboplatin will increase the expression of DAXX protein. Western blot (figure 19) of DAXX
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shows that the Merck GSI has little effect on the expression of the DAXX protein. DAXX protein
expression increases in response to carboplatin. The figure below also confirms that DAXX was
efficiently via siRNA.

Figure 20: Standard of Care Therapy for Triple Negative Breast Cancer Increases DAXX
Expression. MDA-MB-231 cells were transfected with either control or DAXX siRNA for 48
hours. After transfection, cells were grown in 5% IMEM and treated daily with GSI or carboplatin.
After the treatment, cells were lysed, and protein was collected and measured to create samples
for Western blotting. Protein was separated and visualized via Western blot analysis.
Together, these data suggest that DAXX expression is required to increase the sensitivity
of triple negative breast cancer cells to carboplatin. Also, it appears that the DNA damaging agent
is also increasing the expression of DAXX, correlating to the bulk cell proliferation data, where
high DAXX expression increases sensitivity.
DAXX Modestly Limits Proliferation of a Second Triple Negative Cell Line but has Little
Effect on Carboplatin Sensitivity.
To potentially establish if the phenotype seen in MDA-MB-231 cells is cell-type or subtype
specific, a second triple negative cell line, MDA-MB-468, was also transfected with DAXX
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siRNA and treated in a similar manner with carboplatin for 7 days. If the phenotype previously
seen with MDA-MB-231 cells was subtype specific, then it would be expected that DAXX will 1)
significantly limit the proliferation of these cells and 2) be required for the cells to be sensitive to
carboplatin. As seen in figure 20A, DAXX expression limits proliferation of MDA-MB-468 cells,
but only modestly. When it comes to drug sensitivity however, DAXX expression has little effect;
cells are sensitive to carboplatin, whether DAXX is expressed or depleted (figure 20B).

A.

B.

Figure 21: DAXX Expression Limits Proliferation but has No Effect on Drug Sensitivity in
a Second Triple Negative Breast Cancer Cell Line. MDA-MB-468 cells were transfected with
either control or DAXX siRNA for 48 hours. After transfection, cells were grown in 10% FBS
DMEM for 7 days and treated with carboplatin, daily. After treatment the fold change in
proliferation (A.) and percent growth (B.) were calculated.

Table 13: Statistical Significance P-values for Proliferation of DAXX-depleted versus DAXXexpressing MDA-MB-468 Cells.
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DAXX Protein Expression is Decreased in MDA-MB-468 Cells.
If DAXX expression is modulated by standard of care therapy, and depletion of DAXX
results in an increase sensitivity to therapy, then it is expected that DAXX expression will be
decreased—at least in the presence of carboplatin. When MDA-MB-468 cells are treated with
either a GSI or carboplatin, DAXX expression decreased (figure 21), opposite of what was seen
in MDA-MB-231 cells, but consistent with the bulk cell proliferation results. The figure below
also confirms that DAXX was depleted in these cells, via siRNA.

Figure 22: Standard of Care Therapy and Notch Inhibition has No Effect on DAXX
Expression in Second Triple Negative Cell Line. MDA-MB-468 cells were transfected with
either control or DAXX siRNA for 48 hours. After transfection, cells were grown in 10% DMEM
and treated daily with GSI or carboplatin. After the treatment, cells were lysed, and protein was
collected and measured to create samples for Western blotting. Protein was separated and
visualized via Western blot analysis.
DAXX limits Proliferation of Cells in a Third Triple Negative Subtype but is Required for
Resistance to Standard of Care Therapy.
To further determine if the previous phenotype was cell-type or subtype specific, a third
triple negative subtype, BT549, were transfected as well with DAXX siRNA and treated with
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carboplatin for a total of 7 days. Again, if the phenotype previously seen with MDA-MB-231 cells
was subtype specific, then it would be expected that DAXX will both significantly limit the
proliferation of these cells and be required for the cells to be sensitive to carboplatin. In figure
22A, DAXX expression limits the proliferation of cells, more than in the MDA-MB-468 cells. In
terms of drug sensitivity, it appears that low DAXX expression is required for sensitivity to
carboplatin (figure 22B).

A.

B.

Figure 23: DAXX Expression Limits Proliferation but has No Effect on Drug Sensitivity in
a Third Triple Negative Breast Cancer Cell Line. BT549 cells were transfected with either
control or DAXX siRNA for 48 hours. After transfection, cells were grown in 10% FBS RPMI for
7 days and treated with carboplatin, daily. After treatment the fold change in proliferation (A.) and
percent growth (B.) were calculated.
Table 14: Statistical Significance P-values for Proliferation of DAXX-depleted versus DAXXexpressing BT549 Cells.
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Drug Treatments have No Effect on DAXX Protein Expression.
If current forms of therapy modulate DAXX expression, and low DAXX expression
increases sensitivity to this therapy then it is expected that expression of DAXX will decrease upon
treatment with carboplatin. In BT549 cells, DAXX expression remains unchanged, despite
treatment with this therapy (figure 23).

Figure 24: Standard of Care Therapy and Notch Inhibition has No Effect on DAXX
Expression in Third Triple Negative Cell Line. BT549 cells were transfected with either control
or DAXX siRNA for 48 hours. After transfection, cells were grown in 10% RPMI and treated daily
with GSI or carboplatin. After the treatment, cells were lysed, and protein was collected and
measured to create samples for Western blotting. Protein was separated and visualized via Western
blot analysis.
Carboplatin Activates the JNK Signaling Pathway Through DAXX.
Since depletion of DAXX resulted in MDA-MB-231 cells being less sensitive to
carboplatin, then it may be possible that DAXX-expressing cells undergo apoptosis in response to
carboplatin. It is known that DAXX induces apoptosis through activation of JNK signaling
(Salomoni & Khelifi, 2006). Therefore, if MDA-MB-231 cells are more sensitive to carboplatin
due to DAXX-mediated activation of JNK resulting in apoptosis, then there should be an increase
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in phosphorylated (or active) JNK in response to carboplatin when DAXX is expressed and not
when DAXX is depleted. MDA-MB-231 cells were treated similarly as before for 3 days and the
protein expression was detected via Western blot analysis. As seen in the data (figure 24A),
samples that were treated with carboplatin show an increase in phosphorylated JNK. However,
this finding is limited to those cells that are expressing DAXX because once DAXX is depleted,
there is no detection of phosphorylated JNK. This would suggest that DAXX is being upregulated
by carboplatin treatment, subsequently upregulating JNK activity. To

further

asses

that

upregulation of DAXX by carboplatin increases JNK activity, bulk cell proliferation studies were
completed by treating MDA-MB-231 cells with carboplatin as well as SP600125, a JNK inhibitor
(JNKi). Cells were transfected with DAXX siRNA and treated daily for 7 days prior to calculating
the fold change in cell proliferation. If cells expressing DAXX are sensitive to carboplatin due to
an increase in JNK activity, then treating cells with a JNK inhibitor should result in cells that are
resistant to the effects of carboplatin when expressing DAXX. As seen in figure 24B, proliferation
of MDA-MB-231 cells increases when DAXX is depleted when treated with a vehicle or
carboplatin. However, the increase of proliferation in DAXX-depleted cells is attenuated when
JNK activity is inhibited, indicating that there may be a partial role for JNK in overall proliferation.
The addition of carboplatin eliminates the effects seen with the JNKi, regardless of DAXX
expression.
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A.

B.

C.

D.

Figure 25: JNK Activity Regulation Through Carboplatin and DAXX Expression: MDAMB-231 cells were transfected with either control or DAXX siRNA for 48 hours. After
transfection, cells were grown in 5% IMEM and treated daily with (A.) carboplatin for 3 days,
(B.,C.) carboplatin and/or SP600125 for 7 days or (D.) carboplatin and/or SP600125 for 5 days.
After the treatment, cells were either counted and the bulk cell proliferation fold changed
calculated or were lysed, and protein was collected and measured to create samples for Western
blotting. Protein was separated and visualized via Western blot analysis.
DAXX as a Potential Regulator of PARP Activity.
Because DAXX expression is upregulated in response to carboplatin, expression and
cleavage of PARP-1 was measured in treat MDA-MB-231 cells to confirm that these cells fact
were undergoing DNA damage. It is well known that PARP [poly(ADP-ribose) polymerase] is
typically activated in response to DNA damage. Therefore, to determine that these cells were
undergoing some type of DNA damage the expression of PARP-1 was measured. If the cells are
treated with the vehicle, then it is expected that PARP-1 would be cleaved (inactivated) unlike
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those samples that are treated with carboplatin. Additionally, if DAXX is upregulated when treated
with carboplatin, then is the expression of PARP-1 affected by the expression of DAXX? To
answer this and test the hypothesis, MDA-MB-231 cells transfected with DAXX siRNA and
treated with carboplatin were analyzed via Western blot for PARP-1 expression. Interestingly
enough, when DAXX is depleted PARP-1 is smeared, regardless of treatment with carboplatin
(figure 25).

Figure 26: Depletion of DAXX Affects Expression of PARP-1. MDA-MB-231 cells were
transfected with either control or DAXX siRNA for 48 hours. After transfection, cells were grown
in 5% IMEM and treated daily with carboplatin for 3 days. After the treatment, cells were lysed,
and protein was collected and measured to create samples for Western blotting. Protein was
separated and visualized via Western blot analysis.
A recent publication summarized how cells that are under replication or mitotic stress,
PARP activity is key in the re-stabilization of cells (Mcdermott, Buechelmaier, & Powell, 2019).
Activity of PARP-1 includes synthesizing poly(ADP-ribose), or PAR, chains at sites of a single
stranded DNA breaks onto acceptor proteins and to itself. The addition of these chains stabilizes
the replication fork to signal repair factors. To restart the replication fork, another enzyme PARG
[poly(ADP-ribose) glycohydrolase] degrades the PAR chains that have been added. Since
depleting DAXX in MDA-MB-231 cells significantly increases their rate of proliferation and
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causes a smearing effect in PARP-1, total PAR expression was measured in these samples to see
how DAXX expression affects this modification. As seen in figure 25, when DAXX is depleted,
there is an increased smearing effect on the expression of PAR, with or without treatment of
carboplatin—similar to what was seen in PARP-1 expression. Therefore, DAXX could potentially
be regulating, in some way, this PARP/PARG cycle.

Figure 27: Depletion of DAXX Also Increases Smearing of PAR. MDA-MB-231 cells were
transfected with either control or DAXX siRNA for 48 hours. After transfection, cells were grown
in 5% IMEM and treated daily with carboplatin for 3 days. After the treatment, cells were lysed,
and protein was collected and measured to create samples for Western blotting. Protein was
separated and visualized via Western blot analysis.
To determine if DAXX is in fact a regulator of PARP/PARG activity, MDA-MB-231 cells
depleted of DAXX were treated with a PARP-1 inhibitor, olaparib. If DAXX is a regulator of
PARP-1 activity, then treatment with olaparib may reverse this smearing effect seen. As seen in
figure 27, as cells are treated with olaparib for more time, the smearing effect decreases, even
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under conditions where DAXX is depleted. This indicates that there may be in fact a regulatory
role for DAXX in PARP activity.

Figure 28: PARP Inhibitor Decreases Smear Effect in the Absence of DAXX. MDA-MB-231
cells were transfected with either control or DAXX siRNA for 48 hours. After transfection, cells
were grown in 5% IMEM and treated daily with olaparib for 1, 2 or 3 days. After the treatment,
cells were lysed, and protein was collected and measured to create samples for Western blotting.
Protein was separated and visualized via Western blot analysis.

CHAPTER V
DISCUSSION
Out of all the breast cancer subtypes, TNBC is the most aggressive both in terms of
treatment and outcome. Patients with TNBC have a higher risk of recurrence and metastasis, and
unfortunately, do not have many therapeutic options other than chemotherapy. It is known that
DAXX protein appears to be limiting the proliferation of breast cancer cells to some degree in all
the subtypes and in the TNBC subtype does so, significantly. Cell cycle data supports this increase
in proliferation, since there is almost a doubling effect in S-phase once DAXX is depleted (not
shown). This indicates that DNA synthesis is reduced due to DAXX expression, therefore
providing a potential way DAXX is limiting proliferation: via regulation of the cell cycle. It has
also been seen that in a TNBC cell line, MDA-MB-231, DAXX is required for sensitivity to
chemotherapy drug carboplatin. However, in other TNBC cell lines, such as MDA-MB-468 and
BT549, DAXX expression does not limit proliferation or mediate sensitivity to the same extent.
This only emphasizes how diverse and heterogeneous the triple negative subtype truly is, in terms
of several factors such as genes expressed, sensitivity to certain drugs and rate proliferation rates
(Bianchini et al., 2016). This can also be indicative of the extent by which DAXX affects cell
cycling among different subtypes. However, this can only be concluded once the cell cycle of these
other TNBC cell lines and even the other breast cancer subtypes is determined. Although there is
a lot of evidence to support this role of DAXX, the exact mechanism by which DAXX mediates
these processes is still unknown. For example, DAXX limits bulk cell proliferation but how this
occurs exactly has yet to be identified. It was believed that this
70
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mechanism may have been through Notch signaling; however, this hypothesis isn’t strongly
supported anymore.
It also known that DAXX expression is required for activation of JNK when cells are
treated with carboplatin. Because JNK activation leads to apoptosis, it is possible that DAXX is
required for carboplatin sensitivity by activating JNK mediated apoptosis. Cell fractionation
studies primarily localized DAXX to the nucleus, even though it is known that the role DAXX in
terms of JNK activity is in the cytoplasm when it interacts with the Fas death domain. Activated,
or phosphorylated, JNK is also found in the nucleus, therefore it can be hypothesized that DAXX
could be further activating JNK in the nucleus to activate apoptosis of the cell when treated with
carboplatin. This could all indicate that DAXX may be an important biomarker that can potentially
predict how resistant a patient’s cancer or tumor may be to the same therapy.
It has also been seen that DAXX expression appears to be hindering PARP-1 and PAR
expression. PARP-1 works to covalently modify acceptor proteins with PAR chains that stabilize
replication forks in time of distress (i. e. DNA damage). Another enzyme, PARG, removes these
PAR chains once there has been repair to restart the replication process of cells (Mcdermott et al.,
2019). Cancerous cells have increased levels of spontaneous DNA damage and it was implicated
that this PARP/PARG cycle could be a potential targeted therapy in cancer cells. It has been
recently published that DAXX expression increases sensitivity to a PARP inhibitor in the same
MDA-MB-231 cell line, thus inhibiting the ability of PARP-1 to mediate single strand DNA repair
(Shi, Jin, Wang, Ji, & Guan, 2019). Although this is more in relation to DAXX’s ability to mediate
DNA damage response by binding to the promoter region of RAD51, a DNA damage response
gene (Shi et al., 2019). This work is novel since similar results are produced, but in relation to
standard of care therapy in TNBC, thus providing some evidence that a more effective therapy
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may be through PARP inhibition in combination to the current standard of care. Before
determining if this is the case, all elements of this PARP/PARG cycle must be explored. As seen
in figure 28 [adapted from (Mcdermott et al., 2019)], the data supports that DAXX could be
inhibiting PARP-1 activity. However, there is a possibility that DAXX may be activating PARG
activity as well. Data with olaparib, a known PARP-1 inhibitor, supports the hypothesis that
DAXX is regulating PARP-1, but expression and inhibition of PARG has yet to be studied and
could clarify the mechanism by which DAXX is regulating this cycle.

Figure 29: Proposed Role of DAXX Within PARP/PARG Cycle. When DNA is being
replicated, PARP is recruited to sites of ss-DNA breaks to synthesize PAR chains to signal the
recruitment of DNA-repairing enzymes such as DNA ligase III, DNA polymerase beta, and
XRCC1 protein. Once the break is repaired, PARG is recruited to remove these PAR chains and
promote the replication fork to restart and progress the cell cycle. Here, it is shown where and how
DAXX is regulating this mechanism—either by inhibiting PARP activity or by activating PARG
activity.
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Determining where and how DAXX is functioning in this cycle, can not only elucidate yet
another role for this multifunctional role and a clear mechanism by which it is acting by but can
also provide a possible novel form of combinational targeted therapy in a very aggressive subtype.
It has been previously described that cancer patients do not have effective forms of DNA damage
repair mechanism and that TNBC is so aggressive due to a lack of targets. But there is a small
percentage of TNBC patients with a BRCA1 mutation that are responsive to olaparib. BRCA genes
are human tumor suppressor genes that help either repair DNA, through homologous repair, or
destroy cells if DNA cannot be repaired. When there is a mutation in this gene, it results in loss of
function.

When this mutation is present, cells cannot be repaired properly, and they die.

Combining this mutation with a PARP inhibitor results in cells to undergo cell death making a
PARP inhibitor an effective therapy for those patients with this mutation, and this can be seen
summarized in figure 29 (Dziadkowiec, Gąsiorowska, Nowak-markwitz, & Jankowska, 2016).
Since it has been shown that DAXX plays a role in modulating sensitivity of MDA-MB-231 cells
to DNA damaging agent carboplatin, and that DAXX could be potentially be playing a regulatory
role within PARP/PARG, then this could allow for TNBC patients to be stratified into groups that
will be responsive to this combinational targeted therapy, based off of their expression of DAXX
as well as increasing the efficacy of carboplatin.
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Figure 30: Relationship Between PARP Inhibition and BRCA1 Mutations. When there is a
single stranded break (SSB) in the DNA, PARP functions to repair the site of damage (top).
However, when PARP is inhibited and the site cannot be repaired, the SSB results in a double
stranded break (DSB) in which a functional BRCA1 can repair. Loss of function mutations in this
gene, like in some TNBC, result in a buildup of DSB ultimately causing cell death.
The effects of DAXX on the stem cell population is also unknown. In the cell line where
the most significant data in terms of proliferation, effects of standard of care therapy, connection
to JNK and effects on PARP/PAR has been studied, MDA-MB-231, the known stem cell assay,
mammosphere formation assay has been challenging to say the least. Because these cells are
mesenchymal, this assay, which is more for cells that are more basal-like, is not as effective in
studying the stem cell population. Therefore, how DAXX expression affects these cells when
treated with carboplatin remains largely unknown. This stem cell assay could be optimized to
better predict mesenchymal stem cells but a simpler route to begin looking at this population of
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cells could be to look at the expression of genes related to stemness first in these cells via RTqPCR.
Being able to understand the mechanism by which DAXX is behaving can lie within the
roles that have already been determined and characterized. Since DAXX has been localized to the
nucleus, and it is known that in the nucleus DAXX functions as a repressor by associating with
PML nuclear bodies (PML-NB), it is possible that some answers lie there as well. The work that
has been presented does not directly look at DAXX’s repressive role when interacting with these
nuclear bodies. PML is rarely mutated in cancers, but it has been determined that its expression is
lost in human tumors, making it seem like it is a tumor suppressor and is also a regulator of
transcription (Salomoni, 2013). In tumor progression, chromatin levels are altered due to several
factors such as 3D chromosome alterations and abnormal nuclear morphologies which result in
varying levels of nuclear bodies present in the nucleus (Uhler & Shivashankar, 2018). Since there
are 6 subtypes of TNBC alone, all with unique phenotypes and varying expression of genes, then
it is possible that they also vary in the expression of nuclear bodies subsequently affecting the
expression of PML-NB as well. Determining the expression of these PML-NB and how that
expression is affected by DAXX could also provide some insight on how DAXX is mechanistically
behaving differently in different TNBC subtypes or in breast cancer subtypes in general—which
is another route to further progress the results presented.
It has been discussed that DAXX could be involved in several cellular functions such as
proliferation, drug sensitivity, JNK activity, PARP/PARG regulation and hypothesized that there
may be some role in stem like cells as well as PML-NB. But there are still several other cellular
processes that could be responsible for the phenotypes seen, especially since DAXX is a
multifaceted protein. For example, DAXX has been associated with histone modification and
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maintaining heterochromatin and maintaining this function is hypothesized to be key in destroying
cancer tumor cells. Because this is in the nucleus, where are cellular decisions are controlled and
execute in some way, these different cellular functions it appears that DAXX is involved could be
due to a direct involvement with heterochromatin that subsequently results in a number of
pathways to be targeted or implicated in terms of DAXX expression. It is possible that DAXX is
not directly linked to any of the functions listed before; the phenotypes seen are just a by-product
of yet another disrupted process in these cells. Further experiments must be completed in terms of
looking at histone modification to determine the effect of DAXX expression here and the
repercussions of depleting the protein as well on the expression of genes that are heavily involved
in the cellular pathways previously described.
Determining these mechanisms DAXX may be involved in can fully characterize DAXX
to understand its potential as a biomarker. This knowledge can provide insight on how well a
patient will respond to standard of care therapy, specifically in TNBC, to see if 1) said therapy
would even be effective in the first place for them and 2) if it isn’t effective, then what other
therapy may be combined with it to combat the cancer. If the full extent of this protein is studied,
then a new target in TNBC will have been identified that can improve outcome for those with
TNBC. Since it appears that DAXX also limits proliferation in the other subtypes, then
characterizing DAXX in such a way can also determine how a patient may respond to other
therapies of the remaining subtypes. Ultimately, the data supports TNBC more therefore
understanding the complex role of DAXX can allow for more targets to be utilized as
therapeutics—such as JNK and PARP or PARG inhibitors. By improving therapeutics, especially
that of TNBC, will greatly better overall outcome for those with this type of breast cancer,
benefiting those that would have had a poor prognosis and who would suffer much longer the
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effects of chemotherapies. Summarized in figure 30, is a general overview of what has been
learned thus far of DAXX, specifically in the context of TNBC, and the pathways it has been seen
to be affecting.

Figure 31: Final Model Highlighting Key Findings About DAXX. DAXX has been shown to
be primarily localized in the nucleus of MDA-MB-231 cells, where it can be directly linked to its
determined functions. 1. DAXX is limiting the proliferation of cells. 2. Chemotherapy drug,
carboplatin upregulates the expression of DAXX. 3. This upregulation of DAXX coincides with
an increased in JNK activity. Which can be upregulated both in the cytoplasm, where DAXX is
known to function, or even in the nucleus, where DAXX has been localized. And finally, 4. DAXX
expression regulates PARP/PARG cycle by either inhibiting PARP, which has been shown, or
activating PARG, which still needs to be studied.
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